

## +Curriculum Vitae

### James C Blankenship MD, MHCM, MACC, M-SCAI

Department of Cardiology 27-75  
Geisinger Medical Center  
Danville PA 17822  
570-214-1991 Office  
570-854-3712 Cell  
jblankenship@geisinger.edu

Currently Board certified interventional cardiologist, Geisinger Medical Center, Geisinger Health System, Danville, Pennsylvania. Practicing interventional cardiology, nuclear cardiology, inpatient care.  
2016 – present: Chair of Cardiology, Geisinger Health System  
2009 – present: Director of Cardiology, Geisinger Medical Center (GMC)  
2018 – present: Professor of Medicine, Geisinger Commonwealth School of Medicine  
2008 – present: Professor of Medicine (adjunct), Temple Univ Medical College, Phila, PA  
2008 – present: Certified Physician Investigator, Assn of Clinical Research Professionals  
1989 – present: Interventional cardiologist at Geisinger Medical Center, Danville, PA

#### Education

2012-2014 MHCM, Masters of Science (health care management), Harvard Sch of Public Health. GPA 4.0  
1976-1980 MD, Cornell University Medical College, New York City, NY  
1972-1976 AB, magna cum laude in biochemistry, Cornell Univ School of Arts and Sciences, Ithaca, NY.

#### Training

1980-1983 Internal Medicine Internship and Residency, University of Michigan Hospitals, Ann Arbor, MI.  
1984-1987 Cardiology Fellowship, University of Michigan Hospitals, Ann Arbor, Michigan, including nuclear cardiology and interventional cardiology training.

#### Academic Positions

2018- Professor of Medicine, Geisinger Commonwealth School of Medicine, Scranton, PA  
2008- Professor of Medicine (adjunct), Temple University Medical College, Philadelphia, PA  
2000-2008 Professor of Medicine, Jefferson Medical College, Philadelphia, PA  
1998-2000 Professor of Medicine, Hershey Medical College of Penn State University, Hershey, PA  
1989-1998 Clinical Assistant Professor, Hershey Medical College of Penn State University, Hershey, PA  
1987-1989 Clinical Assistant Professor, University of Wisconsin Medical School.

#### Medical Work Experience

1989-present Associate cardiologist, Geisinger Medical Center, Danville, PA  
2011-2014 Founding Director, Evangelical Hospital PCI Program, Lewisburg PA (no surgery on-site)  
1987-1989 Staff cardiologist, Marshfield Clinic, Marshfield, Wisconsin.  
1983-1987 Emergency Physician, Foote Memorial Hospital, Jackson, Michigan.  
1983-1987 Flight Physician, Borgess Inflight Medical Service, Kalamazoo, Michigan.

#### Additional Medical Experience

1984-2018 Served on 19 medical mission teams in the Dominican Republic, Honduras, Guatemala, Bolivia, Haiti, and Ecuador. Medical teams leader, 1993-2014.  
1983-1986 Volunteer physician at Hope Clinic, Ypsilanti, Michigan (a free clinic).  
1983-1986 Emergency physician, Saline Comm Hospital, Saline, MI and Foote Mem Hospital, Jackson, MI.  
1982 Medical resident at Keams Canyon Indian Hosp, Keams Canyon, AZ, for Hopi and Navajos.  
1980 Medical student in Khao-I-Dang Cambodian refugee camp hospital, Aranyaprathet, Thailand.

### Awards and Leadership Positions

2018	Mason Sones Award recognizing outstanding service to SCAI
2004-2017	Director of Central/NE Pennsylvania Level 1 Heart Attack Program
1997-2017	Director of Cardiac Cath Labs and Cardiac Recovery Suite, GMC
2017	“Most Improved” Geisinger award for top 10% in increased patient satisfaction 2016-2017
2016	“Master of SCAI” designation by SCAI
2016-2017	Immediate Past President, SCAI
2016	“Excellence in Leadership” designation by Geisinger (ranked in top 10% physician leaders)
2015-2016	President, SCAI
2014	Teacher of the Month award for January 2014 (highest evaluation by Internal Medicine residents)
2011	“Master of the American College of Cardiology” designation by American College of Cardiology
2005-2011	Chair, Geisinger Administrative Committee for Research
2002-18	Included in “Best Doctors in America” listing
2001- present	Chair, ACC Cardiovascular Relative Value Update Task Force
1997-2003	Chair, Geisinger Scientific Review Committee
1997	Burgess Gordon Award of the Am Med Ass’n for most valuable CPT Advisory Panel Member
1994-1999	Chair, ACC Coding/Nomenclature Committee
1991-1993	Elected to lead the Assembly of Geisinger Clinicians and represent Geisinger associate physicians on the Geisinger Board of Governors.
1980	Charles L. Horn Prize for outstanding leadership and service, Cornell Univ Medical College.
1977-1980	Hirschl Scholarship, Cornell University Medical College, on basis of "...need, outstanding scholarship, and dedication to medical science..."
1976-1980	Medical Student Executive Council, Cornell University Med College. Vice-chair 1977-1978.
1975-1976	President, Cornell University natural history society.
1972-1976	Cornell University National Scholar. Dean's list, three semesters.
1972	Bausch and Lomb Science Award. Dankel Top Biology Student Award. Most outstanding football player-scholar award. Poust Memorial Award for surmounting obstacles. National Merit Scholarship Letter of Commendation.

### Professional Society Service:

#### **American College of Cardiology**

2018-present	Member, Health Affairs Committee
2016-2022	ACC NCDR CathPCI Registry Steering Sub-committee
2016-2022	ACC NCDR CathPCI Registry Research and Publications Sub-committee
2014-2016	Rating Panel for ACC/SCAI Appropriate Use Criteria for PCI in NSTEMI
2014-2017	Member, ACC Interventional Section Leadership Council
2011	Rating Panel for ACC/SCAI Appropriate Use Criteria for Cardiac Cath
2011 -2012	Member, Payment Reform Workgroup
2010 -2013	Member, Council on Clinical Practice
2001- present	Chair, ACC Cardiovascular Relative Value Update Task Force
2000- present	ACC Representative on the American Medical Association Relative Value Update Committee
2000- 2010	Member, ACC Advocacy Committee (member, Advocacy Steering Committee 2007-2010)
2002	Member, Working Group on Live Programs Strategic Planning
1994-2000	ACC rep to American Medical Assoc Current Procedural Terminology (CPT) Advisory Panel
1999-2001	Member, ACC Information Technology Committee
1998-2008	Member, Pennsylvania ACC Chapter Insurance Advisory Expert Panel
1994-1999	ACC representative to the AMA CPT Advisory Panel
1994	Representative from the ACC to the HCFA Single Organ System Exam Task Force.
1992-1993	Represented ACC to HCFA RVW Refinement Panels providing initial RVU values for PTCA.
1989-1999	Member, ACC Economics of Health Care Delivery Committee.
1988	Fellow, American College of Cardiology

## **Society for Cardiac Angiography and Intervention (SCAI) and American Heart Association**

2016-2017	Chair, SCAI Nominations Committee (member 2015-2017)
2016	Testified on behalf of SCAI at FDA Advisory Panel on Bioresorbable Vascular Scaffolds
2016	Member, SCAI executive director search committee
2015-2016	President, SCAI
2014-2015	Co-Chair SCAI Strategic Planning Workgroup
2014-2015	SCAI Maintenance of Certification Working Group
2014-2015	President-Elect, SCAI
2014-2015	Member, executive director transition team, SCAI
2014	Co-Chair, SCAI executive director search committee
2013-2015	Member, "Master of SCAI" selection committee, SCAI
2013-2014	Vice-Chair, ACC/AHA/SCAI wrtg group for Stable Ischemic Heart Disease Guidelines
2013-2014	Vice-President, SCAI
2012-2013	Secretary, SCAI
2011	Developed 1 <sup>st</sup> draft of new CPT codes for coronary intervention
2010-2013	Chair, SCAI Advocacy Committee, member 2010 - 2014
2010-present	Member, SCAI Quality Improvement Committee
2010	Developed 1 <sup>st</sup> draft of new CPT codes for diagnostic catheterization
2010-2015	Member, SCAI Publications Committee
2010-2012	SCAI representative on rating panel for 2012 ACC/AHA/SCAI Diagnostic Catheterization Appropriate Use Criteria
2010-2011	Vice-chair and SCAI representative , ACC/AHA/SCAI writing group for Percutaneous Coronary Intervention Guidelines
2009-2010	Co-Chair, SCAI Budget and Finance Committee
2007-2012	SCAI rep to the ACC/AHA/SCAI writing group for Stable Ischemic Heart Disease Guidelines
2006-2009	Member, SCAI Board of Trustees
1995-2005	Member, SCAI Catheterization Laboratory Performance Committee
1995-present	Fellow, SCAI.
1988-present	Fellow, Council on Clinical Cardiology, American Heart Association.

## U.S. Government Service

2016-2020	Member, FDA Circulatory Device Panel
2016-	Member, CMS MACRA Cardiovascular Disease Clinical Committee

## Licensure, Certification

1999-2029	Interventional Cardiology Board Certification. Passed recertification exam 10/18 in top 6%ile.
1999-2018	Advanced Cardiac Life Support Certification, American Heart Association.
1989	Pennsylvania medical license number MD-043231-E.
1987	Cardiovascular Diseases Board Certification (no expiration)
1987	Nuclear Cardiology Certification, Nuclear Regulatory Commission.
1983	Diplomate, American Board of Internal Medicine (no expiration)

## Committees at Geisinger Medical Center

2016-	Geisinger Health System Coding and Documentation Committee
2016-	Utilization Management Committee
2006 -2012	Director of Interventional Cardiology Fellowship, GMC
2009 -2015	Co-chair of Acute Myocardial Infarction Mortality Reduction Team
2007-2012	Member, Graduate Medical Education Committee
2005-2008	Team Leader, 100,000 Lives Acute MI Team
2005-2011	Chair, Geisinger Administrative Committee for Research. (member 1997-2011)
1999-2004	Founding Director of Interventional Cardiology Fellowship, GMC
1997-2009	Member, Radiation Safety Committee
2000	Member, Graduate Medical Education Review task force
1997-1999	Member, Geisinger-Hershey Cardiology Transition Team.

1997-2000 Member, Cardiology Fellowship Committee, Geisinger Medical System.  
 1995 Geisinger Physician Credentialing Task Force.  
 1994-2003 Member, Geisinger Scientific Review Committee (Chair 2000-2003)  
 1994 Geisinger "Professional Time Away" Task Force  
 1993-1994 Health Promotion/Disease Prevention Ad Hoc Task Force  
 1991-1999 Cardiology Department Quality Improvement Coordinator

### Community Service

2013-present Mentor for Bucknell University Engineering Student Projects  
 2018: Extendable Coronary Artery Stabilizer by R Marchese, R Sahani et al.  
 2014-2015 President, Susquehanna Valley Community Education Project (to start a community college)  
 Board member 2013 - present  
 2013-2014 Chair, District Council, Columbia-Montour Council, Boy Scouts of America  
 2010-2012 Vice-President for Programming, Columbia-Montour Council, Boy Scouts of America  
 1997-2014 Board member, Solid Rock Missions, Archbold, Ohio.  
 1997- 2013 Coached 7 youth soccer and basketball teams  
 1996-2008 Sunday School Teacher, First Baptist Church, Danville, PA  
 1996-present Cub Scout and Boy Scout leader, Danville, PA.  
 2002-2003: Wood Badge adult leadership training course  
 2003, 2006: Leader for Troop 37 Philmont Scout Ranch treks  
 2004 – 2007: Scoutmaster, Troop 37  
 2010 – present: Columbia-Montour Council Executive Board member  
 National Eagle Scout Association, Lifetime member  
 District Award of Merit 2013  
 James West Fellow award 2014  
 1999-2005 Deacon Board member, First Baptist Church, Danville, PA  
 1985-1988 Deacon Board member, Huron Hills Baptist Church, Ann Arbor, Michigan.  
 1981-1983 Speakers Bureau of Physicians for Social Responsibility local chapter, Ann Arbor, Michigan.  
 1976 Empathy and Assistance Referral Service (peer counseling), Cornell University, Ithaca, NY

### Journal Editorial Experience

#### **Journal Editorial Boards:**

Catheterization and Cardiovascular Intervention  
 Journal of Invasive Cardiology  
 American Journal of Cardiology

#### **Reviewer:**

JAMA

Circulation

Circulation: Intervention

Circulation: Outcomes Research

Journal of the American College of Cardiology

JACC: Cardiovascular Interventions

American Journal of Cardiology (1 of 15 "top reviewers" in 2014)

Catheterization and Cardiovascular Intervention ("Frank Hildner Elite Reviewer" in 2015, 2016)

Journal of Invasive Cardiology

American Heart Journal

Chest

American Journal of Medicine

International Journal of Cardiology

### Personal Interests

2010, 2011 Megatransect 26 mile mountain trail run, 3<sup>rd</sup> in 55/o age group. Hyner View Challenge 17 mile mountain run, 3<sup>rd</sup> in 55/o age group  
 2009-18 2018: Summited Mt Aconcagua, Argentina (22,600 feet)

- 2009-2018: 7 winter summits of Mt Washington, New Hampshire  
 2009: Summited Mt Rainier (14,411 feet).  
 2011: 6-day Glacier Skills course by International Mountain Guides, Mt Rainier, WA  
 2015: Summited Mt Kilimanjaro (19,300 feet)
- 2000/01/03 Chesapeake Bay 4.4 mile open water swim races  
 1988 Tin Man Triathlon, Menominee, Wisconsin (9th place).  
 1983 Biathlons at Independence Lake (5th place) and Ann Arbor (4th place), Michigan.  
 1978 Boston marathon (2:50:45)  
 1972-1975 Offensive tackle on 1975 championship Cornell University varsity lightweight football team.  
 Most improved offensive player award, 1974.  
 1968-1972 Eagle Scout, senior patrol leader, graduate of National Junior Leader Instructor Training Course  
 at Schiff Scout Reservation, Mendham, New Jersey.

## Bibliography

### Published Peer-Reviewed Articles

- .125. Dickert NW, Scicluna VM, Adeoye O, Angiolillo DJ, **Blankenship JC**, Devireddy CM, Frankel MR, Goldkind SF, Kumar G, Ko YA, Mitchell AR. Emergency Consent: Patients' and Surrogates' Perspectives on Consent for Clinical Trials in Acute Stroke and Myocardial Infarction. *J Am Heart Assoc* 2019. DOI: 10.1161/JAHA.118.010905.
- .124. Welt FG, Klein LW, Tamis-Holland J, **Blankenship J**, Duffy PL, Cigarroa J, Anderson HV, Views of Appropriate Use Criteria (AUC) for catheterization and percutaneous coronary revascularization by practicing interventional cardiologists: results of a survey of ACC Interventional Section members. *Cathet Cardiovasc Intervent* 2018. DOI:10.1002/ccd.27931
- .123. Seto AH, Shroff A, Abu-Fadel M, **Blankenship JC**, Boudoulas KD, Cigarroa JE, Dehmer GJ, Feldman DN, Kolansky DM, Lata K, Swaminathan RV. Length of stay following percutaneous coronary intervention: An expert consensus document update from the Society for Cardiovascular Angiography and Interventions. *Cathet Cardiovasc Intervent* 2018;92:717-731. <https://doi.org/10.1002/ccd.27637>
- .122. Pancholy MS, Skelding K, Scott T, **Blankenship J**, Pancholy SB. Effect of access site choice on acute kidney injury after percutaneous coronary intervention. *Am J Cardiol* 2017;120:2141-2145.
- .121. Agarwal S, Thakkar B, Skelding KA, **Blankenship JC**. Trends and outcomes after same-day discharge after percutaneous coronary interventions. *Circ Cardiovasc Qual Outcomes*. 2017;10:e003936. DOI: 10.1161/CIRCOUTCOMES.117.003936.
- .120. Kahlon TS, Kumar M, Kline C, Scott E, Berger AL, **Blankenship JC**. Successful prevention of inappropriate cardiac catheterizations by an educational and screening program in a rural tertiary cardiac referral center. *J Am Coll Cardiol Intv* 2017;10:2131-2.
- .119. Jasper R, **Blankenship JC**. Patent foramen ovale closure to prevent secondary neurologic events. *Euro J Int Med* 2017;44:1-1.
- .118. Kahlon TS, Barn K, Akram MM, **Blankenship JC**, Bower-Stout C, Carey DJ, Sun H, Tompkins Weber K, Skelding KA, Scott TD, Green SM. Impact of pre-hospital electrocardiograms on time to treatment and one year outcome in a rural regional ST-segment elevation myocardial infarction network. *Cathet Cardiovasc Intervent* 2017;89:245-51.
- .117. Brown ED, **Blankenship JC**. A Mechanism for stroke complicating thrombus aspiration. *Cathet Cardiovasc Intervent* 2017;89:93-96. DOI: 10.1002/ccd.26682.
- .116. **Blankenship JC**, Duffy P. The value of specialty designation for interventional cardiology. *Cathet Cardiovasc Intervent* 2016;89:97-101. doi/10.1002/ccd.26656/epdf.
- .115. Naidu SS, Aronow HD, Box LC, Duffy PL, Kolansky DM, Kupfer JM, Latif F, Mulukutla SR, Rao SV, Swaminathan RV, **Blankenship JC**. SCAI expert consensus statement: 2016 best practices in the cardiac catheterization

laboratory. *Cathet Cardiovasc Intervent* 2016;88:407-423. DOI: 10.1002/ccd.26551

.114. Klein LW, **Blankenship JC**, Kolansky DM, Dean LS, Naidu SS, Chambers CE, Duffy PL. SCAI position statement concerning coverage policies for percutaneous coronary interventions based on the appropriate use criteria. *Cathet Cardiovasc Intervent* 2016;87:1127-1129.

.113. Gutierrez JA, Harrington RA, **Blankenship JC**, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, G n reux P, Prats J, Deliargyris EN. The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. *Euro Heart J.* 2015 Sep 23;ehv498.

.112. Levine GN, O'Gara PT, Bates ER, **Blankenship JC**, Kushner FG, Ascheim DD, Bailey SR, Bittl JA, Brindis RG, Casey DE Jr, Cercek B, Chambers CE, Chung MK, de Lemos JA, Diercks DB, Ellis SG, Fang JC, Franklin BA, Granger CB, Guyton RA, Hollenberg SM, Khot UN, Krumholz HM, Lange RA, Linderbaum JA, Mauri L, Mehran R, Morrow DA, Moussa ID, Mukherjee D, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Ting HH, Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2015 focused update on primary PCI for patients with STEMI: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *J Am Coll Cardiol* 2015.

.111. **Blankenship JC**, Feldman B, Ranaweera P, Dent J, Huang X, Singer S. The interventional cardiologist as cath lab team leader. *J Inv Cardiol* 2015;27:E98-105.

.110. Berger PB, Kirchner HL, Wagner ES, Ismail-Sayed I, Yahya S, Benoit C, **Blankenship JC**, Carter R, Casale AS, Green SM, Scott TD, Skelding KA, Woods E, Henry YM. Does preoperative platelet function predict bleeding in patients undergoing off pump coronary artery bypass surgery? *J Intervent Cardiol.* doi: 10.1111/joic.12200

.109. **Blankenship JC**, Rosenfield K, Jennings HS. Privileging and credentialing for interventional cardiology procedures. *Cathet Cardiovasc Interv* 2015;86:655-663..

.108. Aranow HD, Gurm HS, **Blankenship JC**, Czeisler CA, Wang TY, McCoy LA, Neely ML, Spertus JA. Middle-of-the-night percutaneous coronary intervention and its association with percutaneous coronary intervention outcomes performed the following day. *J Am Coll Cardiol Intv* 2015;8:49-56.

.107. Gigliotti OS, Babb JD, Dieter RS, Feldman DN, Islam AM, Marmagkiolis K, Moore P, Sorajja P, **Blankenship JC**. Optimal use of left ventriculography at the time of cardiac catheterization: A consensus statement from the Society for Cardiovascular Angiography and Interventions. *Cathet Cardiovasc Intervent* 2015; 85: 181-191.

.106. Baker NC, O'Connell EW, Htun WW, Sun H, Green SM, Skelding KA, **Blankenship JC**, Scott TD, Berger PB. Safety of coronary angiography and percutaneous coronary intervention via the radial versus femoral route in patients on uninterrupted oral anticoagulation with warfarin. *Am Heart J* 2014;168:537-544.

.105. Fihn SD, **Blankenship JC**, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, Fonarow GC, Lange RA, Levine GN, Maddox TM, Naidu SS, Ohman EM, Smith PK, 2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, *J Am Coll Cardiol* 2014;64:1929-1943. (*Circulation* 2014;130:1749-1767)

.104. Dehmer GJ, **Blankenship JC**, Cilingiroglu M, Dwyer JG, Feldman DN, Gardner TJ, Grines CL, Singh M. SCAI/ACCF/AHA expert consensus document update on percutaneous coronary intervention without on-site surgical backup. *Cathet Cardiovasc Interv* 2014;84:169-187. (*Circulation* 2014;129:2610-2626)

.103. Ferrari VA, Whitman B, **Blankenship JC**, Budoff MJ, Costa M, Weissman NJ, Cerqueira MD. Cardiovascular imaging payment and reimbursement systems. *JACC: Cardiovascular Imaging* 2014;7:324-332.

.102. Cubeddu RJ, Palacios IF, **Blankenship JC**, Horvath S, Chu K, Kovacic JC, Dangas G, Witzensbichler B, Guagliumi G, Kornoski R, Dudek D, Stone GW, Mehran R. Outcome of patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention during on-versus off-hours: a HORIZONS-AMI Trial sub-study. *Am J Cardiol* 2013;111:946-954.

.101. Yost GW, Puher SL, Scott TD, Skelding KA, Graham J, Berger PB, **Blankenship JC**. Readmission in the 30 days After Percutaneous Coronary Intervention. *JACC: Cardiovasc Intervent* 2013;6:237-244.

- .100. **Blankenship JC**, Gigliotti OS, Feldman DN, Mixon TA, Patel RAG, Sorajja P, Yakubov SJ, Chambers CE. Ad Hoc percutaneous coronary intervention: a consensus statement from the Society for Cardiovascular Angiography and Interventions. *Cathet Cardiovasc Interv* 2013;81:748-758.
- .99. **Blankenship JC**, Marshall JJ, Pinto DS, Lange RA, Bates ER, Holper EM, Grines CL, Chambers CC. Effect of percutaneous coronary intervention on quality of life: a consensus statement from the Society for Cardiovascular Angiography and Interventions. *Cathet Cardiovasc Interv* 2013;81:243-259.
- .98. Fihn SD, Gardin JM, Abrams J, Berra K, **Blankenship JC**, et al. 2010 ACCF/AHA/ACPAATS/PCNA/SCAI,STS guideline for the diagnosis and management of patients with stable ischemic heart disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2010 Writing Committee to Review New Evidence and Revise the 2002 Guideline for the Management of Patients With Chronic Stable Angina), the American College of Physicians, the American Association for Thoracic Surgery, the Preventive Cardiovascular Nurses Association, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. *J Am Coll Cardiol* 2012;60:2564-2603.
- .97. Baker NC, Ali S, **Blankenship JC**. Left radial artery access to a descending aortic saphenous vein graft to circumflex coronary artery for angioplasty. *J Inv Cardiol* 2012;24: 352-353.
- .96. **Blankenship JC**, Moussa ID, Chambers CC, Brilakis ES, Haldis TA, Morrison DA, Dehmer GJ. Staging of multivessel percutaneous coronary interventions: an expert consensus statement from the Society for Cardiovascular Angiography and Interventions. *Cathet Cardiovasc Interv* 2012;79:1138-1152.
- .95. Crudu V, Sartorius J, Berger PB, Scott T, Skelding K, **Blankenship JC**. Middle-of-the-night PCI does not affect subsequent day PCI success and complication rates by the same operator. *Cathet Cardiovasc Interv* 2012;80:1149-1154.
- .94. Naidu SS, Rao SV, **Blankenship JC**, Cavendish JJ, Farah T, Moussa I, Rihal CS, Srinivas VS, Yakubov SJ. Clinical expert consensus statement on best practices in the cardiac catheterization laboratory: Society for Cardiovascular Angiography and Interventions. *Cathet Cardiovasc Interv* 2012;80:456-464.
- .93. Levine GN, Bates ER, **Blankenship JC**, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *J Am Coll Cardiol* 2011;58:e44-122.
- .92. Crudu V, **Blankenship J**, Berger P, Scott T, Skelding K. Complications related to access site after percutaneous coronary interventions: are the adverse events under-reported? *Cathet Cardiovasc Intervent* 2011;77:643-647.
- .91. Chambers CE, Fetterly KA, Holzer R, Lin P-JP, **Blankenship JC**, Balter S, Laskey WK. Radiation safety program for the cardiac catheterization laboratory. *Cath Cardiovasc Intervent* 2011;77:546-556.
- .90. **Blankenship JC**, Scott TD, Skelding KA, Haldis TA, Tompkins-Weber K, Sledgen MY, Donegan MA, Buckley JW, Sartorius JA, Hodgson JMcB, Berger PB. Door-to balloon times under 90 min can be routinely achieved for patient's transferred for ST-segment elevation myocardial infarction percutaneous coronary intervention in a rural setting. *J Am Coll Cardiol* 2011;47:272-281.
- .89. **Blankenship JC**, Skelding KA, Scott TD, Berger PB, Parise H, Brodie BR, Witzenbichler B, Gaugliumi G, Peruga JZ, Lansky AJ, Mehran R, Stone GW. Predictors of reperfusion delay in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention from the HORIZONS-AMI Trial. *Am J Cardiol* 2010;106:1527-1533.
- .88. Kalyanasundaram A, Scott TD, **Blankenship JC**. Manual aspiration of iatrogenic embolization through a left internal mammary artery graft. *J Inv Cardiol* 2010;22:E115-E118.
- .87. Mokabberi R, **Blankenship JC**. Rotational atherectomy to facilitate stent expansion after deployment in ST-segment elevation myocardial infarction. *Am Heart Hosp J* 2010;8:66-69.
- .86. Welsh RC, Granger CB, Westerhout CM, **Blankenship JC**, Holmes DR, O'Neill WW, Hamm CW, Van de Werf F,

Armstrong PW. Prior coronary artery bypass patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. *J Am Coll Cardiol Interv* 2010;3:343-351.

.85. Kushner FG, Hand M, Smith SC Jr, King SB 3<sup>rd</sup>, Anderson JL, Antman EM, Bailey SR, Bates ER, **Blankenship JC**, Casey DE Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guidelines and 2007 focused update) and the ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guidelines and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines *J Am Coll Cardiol* 2009;54:2205-41.

.84. Berger JS, Roe MT, Gibson CM, Kilaru R, Green CL, Melton L, **Blankenship JC**, Metzger DC, Granger CB, Gretler DD, Grines CL, Huber K, Zeymer U, Buszman P, Harrington RA, Armstrong PW. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y<sub>12</sub> ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI to Optimize REperfusion in Acute Myocardial Infarction (ERASE MI) pilot trial. *Am Heart J* 2009;158:998-1004.

.83. Stone GW, Martin JL, deBoer M-J, Margheri M, Bramucci E, **Blankenship JC**, Metzger C, Gibbons RJ, Lindsay BS, Weiner BH, Lansky J, Krucoff MW, Fahy M, Boscardin WJ; AMIHOT-II Trial Investigators. Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction. *Circ Cardiovasc Interv.* 2009;2:366–375.

.82. **Blankenship JC**, Skelding KA, Scott TD, Buckley J, Zimmerman DK, Temple A, Sartorius J, Jimenez E, Berger PB. ST-elevation myocardial infarction patients can be enrolled in randomized trials before emergent coronary intervention without sacrificing door-to-balloon time. *Am Heart J* 2009;158:400-407.

.81. Lokhandwala JO, Best PJM, Butterfield JH, Skelding KA, Scott T, **Blankenship JC**, Buckley JW, Berger PB. Frequency of allergic or hematologic adverse reactions to ticlopidine among patients with allergic or hematologic adverse reactions to clopidogrel. *Circ Cardiovasc Interv* 2009;2:348-351.

.80. Cai Q, Skelding K, Armstrong A Jr, Desai D, Wood GC, **Blankenship J**. Predictors of long-term major adverse cardiac events and clinical restenosis following elective percutaneous coronary stenting. *Angiology* 2009;60:141-7, 2009.

.79. Good CW, **Blankenship JC**, Scott TD, Skelding KA, Berger PB, Wood GC. Feasibility and safety of ad hoc percutaneous coronary intervention in the modern era. *J Invasive Cardiol* 2009;21:194-200.

.78. Hubbard CR, **Blankenship JC**, Scott TD, Skelding KA, Berger PB. Emergency pretreatment for contrast allergy before direct percutaneous coronary intervention for ST-elevation myocardial infarction. *Am J Card* 2008;102:1469-1472.

.77. **Blankenship JC**, Skelding KA. Rapid triage, transfer, and treatment with percutaneous coronary intervention for patients with ST-segment elevation myocardial infarction. *Acute Coronary Syndromes* 2008;9:59-65.

.76. Kastrati A, Neuman FJ, Mehilli J, Byrne RA, Iijima R, Buttner HJ, Khattab AA, Schulz S, **Blankenship JC**, Pache J, Minners J, Seyfarth M, Graf I, Skelding KA, Dirschinger J, Richardt G, Berger PB, Schomig A. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. *N Eng J Med* 2008; 359: 688-95.

.75. Sarin S, Mouhayar EN, **Blankenship JC**, Costello J, Woomert CA, Nassef LA, Qureshi A. Conservative management of left ventricular pseudoaneurysm guided by cardiac magnetic resonance. *Clinical Cardiology* 2007; 32: E33 - E34

.74. Bhatt DL, Chew DP, Grines C, Mukherjee D, Leeser M, Gilchrist IC, Corbelli JC, **Blankenship JC**, Eres A, Steinhubl S, Tan WA, Resar JR, AlMahameed A, Abdel-Latif A, Tang HW, Brennan D, McErlean E, Hazen SL, and Topol EJ. Peroxisome proliferator-activated receptor  $\gamma$  agonists for the prevention of adverse events following percutaneous coronary revascularization – results of the PPAR study. *Am Heart J* 2007;154:137-43.

.73. Babapulle MN, Diodati JG, **Blankenship JC**, Huynh T, Cugno S, Puri R, Nguyen PA, Eisenberg MJ. Utility of routine exercise treadmill testing early after percutaneous coronary intervention. *BMC Cardiovascular Disorders* 2007;7:12.

- .72. **Blankenship JC**, Haldis TA, Wood CG, Skelding KA, Scott T, Menapace FJ. Rapid triage and transport of patients with ST elevation myocardial infarction for percutaneous coronary intervention in a rural health system. *Am J Cardiol* 2007;100:944-8.
- .71. Wann S, Nassef AL, Jeffrey J, Messer JV, Wilke NM, Duerinckx AJ, **Blankenship JC**, Rosenberg MK, Dembo DH. Ethical considerations in CT angiography. *Int J Cardiovasc Imaging* 2007; 23:379-388.
- .70. Carey BC and **Blankenship JC**. A sequential approach to the management of a massive intracoronary thrombus in ST elevation myocardial infarction. *Angiology* 2007;58:106-111.
- .69. Kalyanasundaram A, **Blankenship JC**, Berger P, Herrmann H, McClure R, Moliterno D. Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: results from TARGET. *Cath Cardiovasc Interv* 2007;69:623-629.
- .68. Cai Q, Skelding KA, Armstrong AT, Desai D, Wood GC, **Blankenship JC**. Predictors of periprocedural creatine kinase-MB elevation complicating elective percutaneous coronary intervention. *Am J Cardiol* 2007;99:616-620.
- .67. Dehmer GJ, **Blankenship JC**, Wharton TP, Seth A, Morrison DA, DiMario C, Muller D, Kellet M, Uretsky BF. The current status and future direction of percutaneous coronary intervention without on-site surgical backup: an expert consensus document from the Society for Cardiovascular Angiography and Interventions. *Cath Cardiovasc Interv* 2007 69:471-478.
- .66. Haldis YA, Fenster B, Gavlick K, Singh K, Iliadis E, **Blankenship JC**. The angiographic step-up and step-down: a surrogate for optimal stent expansion by intravascular ultrasound. *J Inv Cardiol* 2007; 19:101-105.
- .65. Eisenberg MJ, Wilson B, Lauzon C, Huynh T, Eisenhauer M, Mak KH, **Blankenship JC**, Douce M, Pilote L. Routine functional testing after percutaneous coronary intervention: results of the Aggressive Diagnosis of Restenosis in High-Risk Patients (ADORE II) trial. *Acta Cardiol* 2007 (in press)
- .64. Hubbard R, **Blankenship J**, Haldis T. Rescue of CardioSEAL PFO closure device malposition with Amplatzer PFO closure device at time of initial implantation. *Cath Cardiovasc Interv* 2007; 69:285-288.
- .63. Schweiger MJ, Chambers CE, Davidson CJ, Zhang S, **Blankenship JC**, Bhalla N, Block PC, Dervan JP, Gasperetti C, Gerber L, Kleiman NS, Krone RJ, Phillips WJ, Siegel RM, Uretsky BF, Laskey WK. Prevention of contrast induced nephropathy: recommendations for the high risk patient undergoing cardiovascular procedures. *Cath Cardiovasc Interv* 2007;69:135-140.
- .62. Aslam F, Iliadis EA, **Blankenship JC**. Percutaneous closure of patent foramen ovale: success and outcomes of a low volume procedure at a rural medical center. *J Inv Cardiol* 2007;19:20-24.
- .61. Krone RJ, Shaw RE, Klein LW, **Blankenship JC**, Weintraub WS. Ad hoc percutaneous coronary interventions in patients with stable coronary artery disease - a study of prevalence, safety, and variation in use from the American College of Cardiology National Cardiovascular Data Registry (ACC-NCDR). *Cath Cardiovasc Interv* 2006;68:696-703.
- .60 Gibson CM, Karpaliotis D, Kosmidou I, Murphy SA, Kirtane AJ, Budiu D, Ray KK, Herrmann HC, Lakkis N, Kovach R, French W, **Blankenship J**, Lui HH, Palabrica T, Jennings LK, Cohen DJ, Morrow DA. Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome. *Am J Cardiol* 2006;97:1473-1477.
- .59. Chambers CE, Eisenhauer MD, McNicol LB, Block PC, Phillips W, Dehmer GJ, Heupler FA, **Blankenship JC**. Members of the Catheterization Lab Performance Standards Committee for the Society for Cardiovascular Angiography and Interventions. Infection control guidelines for the cardiac catheterization laboratory: society guidelines revisited. *Catheterization & Cardiovascular Interventions* 2006;67:78-86.
- .58. Gavlick K, **Blankenship JC**. Snare retrieval of the distal tip of a fractured rotational atherectomy guidewire: roping the steer by its horns. *J Inv Cardiol* 2005;17:E55-E58.
- .57. Laureti JM, Singh K, **Blankenship J**. Anomalous coronary arteries: a familial clustering. *Clin Cardiol* 2005;28:488-

.56 **Blankenship JC**, Haldis T, Feit F, Hu T, Kleiman NS, Topol EJ, Lincoff AM. Angiographic adverse events, creatine kinase-MB elevation, and ischemic endpoints complicating percutaneous coronary intervention (a REPLACE-2 Substudy). *Am J Cardiol* 2006;97:1591-1596.

.55 Aslam F. **Blankenship JC**. Coronary artery stenting in patients with severe left ventricular dysfunction. *J Inv Cardiol* 2005;17:656-658.

.54 Krucoff MW, Crater SW, Gallup D, **Blankenship JC**, Cuffe M, Guarneri M, Krieger RA, Kshetry VR, Morris K, Oz M, Pichard A, Sketch MH, Koenig HG, Mark D, Lee KL. Music, imagery touch and prayer as adjuncts to interventional cardiac care: the Monitoring and Actualisation of Noetic Trainings (MANTRA) II randomized study. *Lancet* 2005;366:211-17.

.53 Saririan M, Cugno S, **Blankenship J**, Huynh T, Sedlis S, Starling M, Pilote L, Wilson B, Eisenberg MJ. Routine versus selective functional testing after percutaneous coronary intervention in patients with diabetes mellitus. *J Inv Cardiol* 2005;17:25-29.

.52 Cantor WJ, Tcheng JE, **Blankenship JC**, O'Shea JC, Pieper KS, Criger DA, Madan M, Ducas J, Sheldon WS, Tannenbaum MA, Smith JE, Kitt MM, Gilchrist IC. Temporal spectrum of ischemic complications with percutaneous coronary intervention: the ESPRIT experience. *J Invasive Cardiol*. 2004 Sep;16(9):475-81.

.51 Tadros, GM, Islam MA, Mirza A, **Blankenship JC**, Iliadis EA. Angiographic and long-term outcomes of "rescue" stenting versus PTCA in failed thrombolysis in acute myocardial infarction. *Angiology*. 2004;55(2):169-76.

.50 Exaire JE, Dauerman HL, Topol EJ, **Blankenship JC**, Wolski K, Raymond RE, Cohen EA, Moliterno DJ. Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices. *Am Heart J*. 2004;147(1):31-4.

.49 **Blankenship JC**, Klein LW, Laskey WK, Krone RJ, Dehmer GJ, Chambers C, Cowley M. SCAI statement on ad hoc versus the separate performance of diagnostic cardiac catheterization and coronary intervention. *Catheter Cardiovasc Interv* 2004: 63; 444-451.

.48 **Blankenship JC**. Ethics in interventional cardiology: combining coronary intervention with diagnostic catheterization. *Am Heart Hosp J* 2004; 2: 52-54.

.47 **Blankenship JC**, Islam A, Wood CG, Iliadis EA. Angiographic adverse outcomes during percutaneous coronary intervention fail to predict creatine kinase-MB elevation. *Catheter Cardiovasc Interv* 2004;63:31-41.

.46 Eisenberg MJ, **Blankenship JC**, Huynh T, Azrin M, Pathan A, Sedlis S, Panja M, Starling MR, Beyar R, Azoulay A, Caron J, Pilote L. Evaluation of routine functional testing after percutaneous coronary intervention. *Am J Cardiol* 2004;93:744-747.

.45 Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, **Blankenship JC**, Kerensky R. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. *JAMA* 2003;290:2292-2300.

.44 Ross MJ, Hermann HC, Moliterno DJ, **Blankenship JC**, Demopoulos L, DiBattiste PM, Ellis SG, Ghazzal Z, Martin JL, white J, Topol EJ. Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition. *J Am Coll Cardiol* 2003;42:981-8.

.43 Tadros GM, Mouhayar EN, Akinwnde AO, Campbell B, Wood C, **Blankenship JC**, Iliadis EA. Prevention of radio-contrast-induced nephropathy with N-acetylcysteine in patients undergoing coronary angiography. *J Inv Cardiol* 2003;15:311-314.

.42 Mouhayar EN, **Blankenship JC**, Fenster BD, Iliadis EA, McConnell TR. Coronary artery "pseudothrombus" due to collateral flow artifact distal to left circumflex coronary stenosis. *J Interven Cardiol* 2002;15:425-430.

.41 **Blankenship JC**, Balog C, Sapp SK, Califf RM, Lincoff AM, Tcheng JE, Topol EJ. Reduction in vascular access site

bleeding in sequential abciximab coronary intervention trials. *Cathet Cardiovasc Intervent* 2002;57:476-483.

.40 Islam MA, **Blankenship JC**, Balog C, Iliadis EA, Lincoff AM, Tcheng JE, Califf RM, Topol EJ. Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). *Am J Cardiol* 2002;90:916-921.

.39 Haldis TA and **Blankenship JC**. Telephone reporting in the consultant-generalist relationship. *J Eval Clin Practice* 2002;8:31-35.

.38 **Blankenship JC**, Sigmon KN, Pieper KS, O'Shea CO, Tardiff BE, Tcheng JE. Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT (Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II Trial. *Am J Cardiol* 2001;88:969-973.

.37 **Blankenship JC**, Tasissa G, O'Shea JC, Iliadis EA, Bachour FA, Cohen DJ, Lui HK, Mann T, Cohen E, Tcheng JE. Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial. *J Am Coll Cardiol* 2001;38:653-8.

.36 Islam MA, **Blankenship JC**, Iliadis EA. Effectiveness of transluminal extraction atherectomy for debulking spahenous vein graft in-stent restenosis. *Cathet Cardiovasc Diagn* 2001;87:785-788.

.35 Dasgupta H, **Blankenship JC**, Demko SL, Menapace FJ. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. *Am Heart J* 2000;140:206-211.

.34 Memon MA, **Blankenship JC**, Wood CG, Frey CM, Menapace FJ. Incidence of Intra-Cranial Hemorrhage Complicating Treatment with Glycoprotein IIb/IIIa Receptor Inhibitors: a Pooled Analysis of Major Clinical Trials. *Am J Med* 2000;: 213-217.

.33 Thel MD, Califf RM, Tardiff BE, Gardner LH, Sigmon KN, Lincoff AM, Topol EJ, Kitt MM, **Blankenship JC**, et al. Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT II). *Am J Cardiol* 2000;33:427-34.

.32 **Blankenship JC**, Mishkel G, Chambers CE, Hodgson JM, Holmes DR, Sheldon W, Schweiger MJ, Cowley MJ, Popma JJ. Ad hoc coronary angioplasty: a position paper of the Society for Cardiac Angiography and Intervention. *Cath Cardiovasc Intervent* 2000;491:30-134.

.31 **Blankenship JC**. Bleeding complications of glycoprotein IIb/IIIa receptor inhibitors. *Am Heart J* 1999;138:S287-S296.

.30 **Blankenship JC**, Menapace FJ, Fox LS, Frey CM. Telephone reporting of cardiac procedure results: feasibility and primary care physician preferences. *Am J Med* 1999;106:521-526.

.29 **Blankenship JC**, Bateman TM, Haines DE, Pearlman AS, et al. American College of Cardiology expert consensus document on ethical coding and billing practices for cardiovascular medicine specialists. *J Am Coll Cardiol* 1999;33:1076-1086.

.28 **Blankenship JC**, Krucoff MW, Werns SW, Anderson HV, Landau C, White HJ, Green CL, Spokojny AM, Bach RG, Russell RE, Pinkston J, Rawart M, Talley JD. Comparison of slow oscillating versus fast balloon inflation strategies for coronary angioplasty. *Am J Cardiol* 1999;83:675-680.

.27 Tardiff BE, Califf RM, Tcheng JE, Lincoff AM, Sigmon KN, Harrington RA, Mahaffey KW, Ohman EM, Teirstein PS, **Blankenship JC**, Kitt MM, Topol EJ, for the IMPACT II Investigators. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. *J Am Coll Cardiol* 1999;33:88-96.

.26 Bhagwandien NS, Shah N, Costello JM, Gilbert CL, **Blankenship JC**. Echocardiographic detection of pulmonary valve fibroelastoma. *J Cardiovasc Surg* 1998;39:351-354.

.25 **Blankenship JC**, Ford AC. Therapeutic repositioning of a Gianturco-Roubin II coronary stent after initial deployment. *Cathet Cardiovasc Diagn* 1998;45:57-60.

- .24 Chu KH, Menapace FJ, **Blankenship JC**, Hausch R, Harrington T. Polyarteritis nodosa presenting as acute myocardial infarction with coronary dissection. *Cathet Cardiovasc Diagn* 1998;44:320-324.
- .23 Mandak JS, **Blankenship JC**, Gardner LH, Berkowitz SD, Aguirre FV, Sigmon KN, Timmis GC, Gilchrist IC, McIvor M, Resar J, Weiner BH, George BS, Talley JD, Lincoff AM, Tchong JE, Califf RM, Topol EJ, Califf RM for the IMPACT II Investigators. Modifiable Risk Factors for Vascular Access Site Complications in the IMPACT II Trial of Angioplasty with versus without Eptifibatide. *J Am Coll Cardiol* 1998;31:1518-1524.
- .22 **Blankenship JC**, Hellkamp AS, Aguirre FV, Demko SL, Topol EJ, Califf RM. Vascular access site complications after percutaneous coronary interventions with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. *Am J Cardiol* 1998;81:36-40.
- .21 **Blankenship JC**, Scheiber J, Menapace FJ. Telephone reporting of cardiac procedure results to primary care physicians. *Am J Cardiol* 1997;79:984-986.
- .20 Lefkovits J, **Blankenship JC**, Anderson KM, Stoner GL, Weisman HF, Worley S, Talley JD, Worley SJ, Weisman HF, Califf RM, Topol EJ for the EPIC Investigators. Platelet dependency of the increased risk of non-Q-wave MI following directional atherectomy. Evidence from the EPIC trial. *J Am Coll Cardiol* 1996;28:849-855.
- .19 **Blankenship JC**. Right coronary artery pseudo-transection due to mechanical straightening during coronary angioplasty. *Cathet Cardiovasc Diagn* 1995;36:43-45.
- .18 **Blankenship JC**, Nguyen DH, Sirimanne L. Oscillating balloon angioplasty: Does pressure oscillation reach the balloon? *Cathet Cardiovasc Diagn* 1996;37:109-112.
- .17 Aguirre FV, Topol EJ, Ferguson JJ, Anderson K, **Blankenship JC**, Heuser RR, Sigmon K, Taylor M, Gottlieb R, Hanovich G, Rosenberg M, Donohue TJ, Weisman HF, Califf RM for the EPIC Investigators. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa Integrin in patients undergoing percutaneous coronary intervention. *Circ* 1995;91:2882-2890.
- .16 **Blankenship JC**, Narke JA, Roberts JW. Transluminal extraction catheter atherectomy in long saphenous vein grafts. *Cathet Cardiovasc Diagn* 1995;35:368-372.
- .15 **Blankenship JC**, Ford AC, Henry SD, Frey CM. Coronary dissection resulting from angioplasty with slow oscillating versus rapid inflation and slow versus rapid deflation. *Cathet Cardiovasc Diagn* 1995;34:202-209.
- .14 **Blankenship JC**, Butler M, Garbes A. Prospective assessment of cholesterol embolization in patients with acute MI treated with thrombolytic versus conservative therapy. *Chest* 1995;107:662-668.
- .13 Burnside J, Costello JM, Angelastro NJ, **Blankenship J**. Forearm compartment syndrome following thrombolytic therapy for acute MI. *Clin Cardiol* 1994; 17:345-347.
- .12 Wall TC, Califf RM, **Blankenship JC**, Talley JD, Tannenbaum M, Schwaiger M, Gacioch G, Cohen MD, Sanz M, Leimberger JD, Topol EJ for the TAMI 9 Research Group. Intravenous fluosol in the treatment of acute MI. *Circ* 1994; 90:114-120.
- .11 **Blankenship JC**, Telesford LA, Modesto TA. A randomized study of sheaths versus guidewires for arterial access during elective cardiac catheterization. *J Inv Cardiol* 1994; 6:186-193.
- .10 **Blankenship JC**. Acute occlusion of a remote coronary artery complicating directional coronary atherectomy. *Cathet Cardiovasc Diagn* 1993; 30:214-219.
- .9 **Blankenship JC**, Indeck M. Spontaneous splenic rupture complicating anticoagulant or thrombolytic therapy. *Am J Med* 1993; 94:433-437.
- .8 **Blankenship JC**, Madigan NP, Modesto T. Acute MI complicating chronic urokinase infusion for totally occluded saphenous vein graft. *Cathet Cardiovasc Diagn* 1993; 28:39-43.
- .7 Grines CL, Nissen SE, Booth DC, Gurley JC, Chelliah N, Wolf R, **Blankenship J**, Branco MC, Bennett K, DeMaria

AN, and the KAMIT group. A prospective randomized trial comparing combination half-dose tPA and SK with full-dose tPA. *Circulation* 1991; 84:540-549.

.6 **Blankenship JC**. Catheterization in patients with dextrocardia. *Cathet Cardiovasc Diag* 1991; 23:103-106.

.5 **Blankenship JC**. Median and ulnar neuropathy after streptokinase infusion. *Heart and Lung* 1991; 20:221-223.

.4 **Blankenship JC**, Almquist AK. Cardiovascular complications of thrombolytic therapy in patients with a mistaken diagnosis of acute myocardial infarction. *J Am Coll Cardiol* 1989; 14:1579-1582.

.3 **Blankenship JC**. Spinal cord infarction resulting from cardiac catheterization. *Am J Med* 1989; 87:239-240.

.2 **Blankenship JC**. Multiple cholesterol embolization after intravenous thrombolytic therapy and catheterization for acute myocardial infarction. *J Invasive Cardiology* 1989; 1:175-179.

.1 **Blankenship JC** and Thomas RB. Demographic impact of introducing modern medicine to a subsistence-level agrarian population: a simulation. *Environmental Management* 1977; 1(5):401-417.

## **Non Peer-Reviewed Publications**

.61. **Blankenship JC**. Day-after PCI: safe for the patient but perhaps not for the interventionalist. *Cathet Cardiovasc Interv* 2018;92. DOI: 10.1002/ccd.27965.

.60. **Blankenship JC**. PFO closure: where are the neurologists? *Cathet Cardiovasc Interv* 2018;92:187-8. DOI:10.1002/ccd.27699

.59. **Blankenship JC**. They think you earn too much but they probably don't care. *Cathet Cardiovasc Interv* 2018;91:1068-9. dx.doi.org/10.1002/ccd.27626.

.58. **Blankenship JC**. Patient preferences prompt peek at priorities. *Cathet Cardiovasc Interv* 2017;90:364-365. DOI: 10.1002/ccd.27304.

.57. **Blankenship JC**. Slow and steady may win this race. *Cathet Cardiovasc Interv* 2017;90:241-2. DOI: 10.1002/ccd.27228

.56. **Blankenship JC**. The compleat radialist. *J Inv Cardiol* 2017;29:225-226.

.55. **Blankenship JC**. Thrombus aspiration: suck it up and keep looking for a niche. *Cathet Cardiovasc Interv* 2016; 88:725-726 DOI: 10.1002/ccd.26822

.54. **Blankenship JC** and Wieggers SE. Concerns regarding "2015 ACR/ACC/AHA/AATS/ACEP/ASNC/NASCI/SAEM/SCCT/SCMR/SCPC/SNMML/STR/STS: Appropriate Utilization of Cardiovascular Imaging in Emergency Department Patients with Chest Pain". *Cathet Cardiovasc Interv* 2016;87:1124-1126. DOI: 10.1002/ccd.26467

.53. **Blankenship JC**, Abbott B, Lindenfeld J, Wieggers S, Rosenfield K. The value of sub-specialty society membership. *Cathet Cardiovasc Interv* 2016;88:671-673.

.52. **Blankenship JC**. Passion: a day in the life of an interventionalist. *Cathet Cardiovasc Interv* 2016;87:999-1000. DOI: 10.1002/ccd.26531

.51. **Blankenship JC**. When in doubt, aspirate. *Cathet Cardiovasc Interv* 2016;87:648-649.

.50. **Blankenship JC**. Facing disasters. *Cathet Cardiovasc Interv*. 2016;87:639-41

.49. **Blankenship JC**. SCAI's future: the 2016 strategic plan. *Cathet Cardiovasc Interv* 2016;87:183-187.

.48. Kavinsky CJ, McElhinney DB, **Blankenship JC**. SCAI: The voice of congenital and structural heart disease (CHD/SHD) interventionalists. *Cathet Cardiovasc Interv* 2016; (in press)

- .47. **Blankenship JC**. A call for SCAI members to become physician leaders. *Cathet Cardiovasc Interv* 2016;87:1-2.
- .46. **Blankenship JC**. The oculo-thrombotic reflex: why we will never stop aspirating coronary thrombi. *JACC: Cardiovasc Interv* 2016;9:123-125.
- .45. Blankenship JC. Professionalism in interventional cardiology and the new value-based payment system. *Cathet Cardiovasc Interv* 2015;86:961-964.
- .44. **Blankenship JC**. Advocate for our patients, advocate for our profession. *Cathet Cardiovasc Interv* 2015;86:787-790.
- .43. Rao SL, **Blankenship JC**. SCAI: enhancing patient care through quality. *Cathet Cardiovasc Interv* 2015;86:1-2.
- .42. **Blankenship JC**. Optimism and interventional cardiology. *Cathet Cardiovasc Interv* 2015;86:183-185.
- .41. **Blankenship JC**. Glance backward before forging ahead: strategically mapping SCAI's future. *Cathet Cardiovasc Interv* 2015;85:1109-1101.
- .40. **Blankenship JC**. The importance of leadership in the cath lab. *Cathet Cardiovasc Interv* 2015;86:361-363.
- .39. Baker JL, **Blankenship JC**. SCAI welcomes the rest of the cath team. *Cathet Cardiovasc Interv* 2015;86:609-610.
- .38. **Blankenship JC**. The power of the story in an era of big data and huge databases. *J Inv Cardiol* 2015;27:33-34.
- .37. **Blankenship JC** and Berger PBB. A radial resolution to a warfarin worry. *Cathet Cardiovasc Interv* 2015;85:89-90.
- .36. **Blankenship JC**. Chronic total quality of life. *Cathet Cardiovasc Interv* 2014;84:635-636.
- .35. **Blankenship JC**, Scott TD. What matters and what does not: variations in STEMI PCI techniques. *Cathet Cardiovasc Interv* 2014;83:727-728.
- .34. Yost GW, **Blankenship JC**, Berger PBB. Managing 30-day readmissions after PCI. *Cardiac Interventions Today* 2014;Jan/Feb: 53-55.
- .33. **Blankenship JC**, Miller SC. Risky business: when patient preferences seem irrational. *Cathet Cardiovasc Interv* 2013;82:219-220.
- .32. **Blankenship JC**, Marshall JJ. Reimbursement for coronary intervention. *Cathet Cardiovasc Interv* 2013;81:745-747.
- .31. **Blankenship JC** and Kavinsky CJ. The new 2013 coronary intervention codes. *Cardiac Interventions Today* 2013;Mar/Apr:23-27.
- .30. **Blankenship JC** and Marshall JJ. Reimbursement changes with new PCI codes in 2013. *Cathet Cardiovasc Interv* 2012;80:1057-1059
- .29. **Blankenship JC** and Kavinsky C. New codes for coronary interventions allow reimbursement for complex procedures. *Cardiology Today's Intervention* 2013 Jan/Feb:8-10.
- .28. Biga C, **Blankenship JC**, Campbell R, DeCara JM, Erb BD, Hines JL, Itchhaporia D, Jaskie S, Kim D, Minissian MB, Phillips M, Poppas A, Seides SF, Thomas GS, Valentine CM, Victor M, Walpole HT, Wann LS, Wolk MJ. Developing and managing a successful CV service line. An ACC Council on Clinical Practice white paper. Monograph. August 2012.
- .27. **Blankenship JC**. AMA and CMS: Productive collaboration or pathologic collusion? *Cardiosource.com*. (American College of Cardiology website) <http://paymentinnovations.cardiosource.org/Article-of-the-Month/2012/07/AMA-and-CMS-Productive-Collaboration-or-Pathologic-Collusion.aspx>. Posted July 6, 2012
- .26. **Blankenship JC**. Progress towards doing the right thing. *JACC: Cardiovasc Interv* 2012;5:236-237.

- .25. **Blankenship JC**. Take that, stent nihilists: additional evidence for the benefits of coronary stenting. *Cardiovasc Intervent* 2011;78:177-178.
- .24. **Blankenship JC**. Complacency, begone. *Cathet Cardiovasc Intervent* 2010;76:491-492.
- .23. **Blankenship JC**. Double jeopardy, double trouble. *Cathet Cardiovasc Intervent* 2010;76:279-280.
- .22. **Blankenship JC**. The sticky story of stuck stents. *J Inv Cardiol* 2010;22:117-118.
- .21. **Blankenship JC**. Quality metrics for each component of the STEMI care system. *Cathet Cardiovasc Intervent* 2009;74:835-836.
- .20. **Blankenship JC**, Williams SH. Rapid transfer for ST-elevation myocardial infarction PCI: it's just not that hard! *J Inv Cardiol* 2009;21:434-436.
- .19. **Blankenship JC**. Here today, gone today: time for same-day discharge after PCI. *Cathet Cardiovasc Intervent* 2008;72:626-628.
- .18. **Blankenship JC**. Toward a coherent strategy for post-dilatation. *J Inv Cardiol* 2008;20:347-348.
- .17. **Blankenship JC**. Parsing the subsets: when small studies create confusion. *Cathet Cardiovasc Intervent* 2008;72:23-24.
- .16. **Blankenship JC**. The peri-PCI enzyme rise: Speed bump or springboard to disaster. *Cathet Cardiovasc Intervent* 2008;71:325-6.
- .15. **Blankenship JC**. Jump on the bandwagon now or chase the rocket later. *Cathet Cardiovasc Intervent* 2008;71:158-9.
- .14. Kalyanasundaram A, **Blankenship JC**, Shirani J. Non-ST segment elevation acute coronary syndromes. *Southern Med J* 2006;99:1053-1054.
- .13. Bottner RK, **Blankenship JC**, Klein LW. International Committee of the Society for Cardiovascular Angiography and Interventions. Current usage and attitudes among interventional cardiologists regarding the performance of percutaneous coronary intervention (PCI) in the outpatient setting. *Cathet Cardiovasc Intervent* 2005;66:455-461.
- .12. **Blankenship JC**. Slotted-tube and self-expanding stents have similar restenosis rates in long segment coronary disease. *Evidence-based Cardiovascular Medicine* 2002;6:109-110.
- .11. **Blankenship JC** and Iliadis EA. Coronary magnetic resonance angiography. *New England J Med* 2002;346:1413. (letter)
- .10. **Blankenship JC** and Iliadis EA. Platelets and coronary intervention: some practical precautions. (editorial) *J Inv Cardiol* 2000;12:536-538.
- .9. **Blankenship JC**. The telephone booth: a worthwhile stop along the information superhighway. (editorial) *Am J Med* 2000;108:592-593.
- .8. Madan M, **Blankenship JC**, Berkowitz SD. Bleeding complications with platelet glycoprotein IIb/IIIa receptor antagonists. *Curr Opin Hematol* 1999;6:334-341.
- .7. **Blankenship, JC**. Cholesterol embolisation after thrombolytic therapy. *Drug Safety* 1996; 14:78-84.
- .6. **Blankenship JC**. Intra-coronary thrombus in a patient with post-infarct angina. *Cath-Lab Digest*, October 1996: 7.
- .5. **Blankenship JC**. The workhorse balloon, part 2: balloon technology. *Cardio Interv* 1994 October:10-16.
- .4. **Blankenship JC**. House staff graduation address: Voluntarism in medicine. *Geisinger Bulletin* 1994; 44:28-30.
- .3. **Blankenship JC**. The workhorse balloon, part I: inflation technique. *Cardio Interv* 1994; 4:10-16.

.2. **Blankenship JC**. The right road for medicine. *J Am Med Assoc* 1993; 270:1546 (letter).

.1. **Blankenship JC**, Indeck M. Spontaneous splenic rupture complicating thrombolytic therapy for acute myocardial infarction. *NEJM* 1991; 325:969 (research letter).

## Abstracts

.100. Jha K, **Blankenship JC**. Clinical Efficacy of 13-Hour Premedication Regimen for Contrast Allergy before Percutaneous Coronary Intervention. *Cathet Cardiovasc Interv* 2019. In Press.

.99. Brown E, Dumandan C, Mahmood M, **Blankenship J**. Improving the safety profile of diagnostic coronary bypass angiography. *J Am Coll Cardiol* 2017;11(69):1089.

.98. Al-Azizi KM, Alabbady AM, Burnside JA, Stella JJ, Green SM, Scott TD, **Blankenship JC**, Skelding KA. CRT-800.26 Validation of the Contrast Induced Nephropathy Risk Score In Patients Undergoing Transcatheter Aortic Valve Replacement. *JACC: CV Intervent*. 2017;3:S71 (abstr).

.97. Al-Azizi K, Alabbady AM, Burnside JA, Stella JJ, Green SM, Scott TD, **Blankenship JC**, Skelding KA. CRT-800.28 The CIN-IT Study:-Contrast Induced Nephropathy In Patients Undergoing Transcatheter Aortic Valve Replacement. *JACC: CV Intervent*. 2017;3:S72 (abstr).

.96. Pancholy SB, Pancholy MS, Skelding K, Scott T, **Blankenship J**. Impact of access site on incident contrast-induced nephropathy after percutaneous coronary intervention. *J Am Coll Cardiol* 2016;67:88.

.95. Scicluna VM, **Blankenship JC**, Devireddy CM, Frankel M, Goldkind SF, Kumar G, Long Q, Mitchell AR, Nogueira RG, Noreen S, Parker RM. Patient centered approaches to research enrollment (P-CARE). *Circulation*. 2016;134(Suppl 1):A15108 (abstr).

.94. Htun WW, Vijayakrishnan R, Awdisho A, Syed I, Kaur S, Verma B, Ferrari AM, Henry YM, **Blankenship JC**, Berger PB. Safety and Cost Effectiveness of Same Day Discharge After Elective Percutaneous Coronary Interventions: A Large Rural Single Center Experience. *Circulation*. 2015 Nov 10;132(Suppl 3):A18759 (abstr).

.93. Doddamani S, Sun H, Forster K, Adams J, Henry Y, Fesniak H, **Blankenship J**, Berger P. Frequency and long-term outcomes of patients with asymptomatic left-ventricular dysfunction. *J Am Coll Cardiol* 2015;65:A191 (abstr).

.92. **Blankenship JC**, Vandermark WA, Pfeiffer J, Krex SM, Schneider TA, Berger. Improved case mix index due to imbedded clinical documentation improvement specialists on inpatient cardiology service at a tertiary medical center. *J Am Coll Cardiol* 2015;65:A243 (abstr).

.91. **Blankenship JC**, Bower-Stout C, Scott T, Skelding K, Berger P. Pre-hospital cath lab activation is associated with decreased mortality after PCI for STEMI. *Cathet Cardiovasc Interv* 2015;85:Supp 2: S3. (abstr).

.90. Rasanias S, Suryadevara R, Berger PB, Green SM, Scott T, Skelding KA, Feng W, **Blankenship JC**. A randomized controlled trial to assess operator radiation exposure from cardiac catheterization procedures using a RAD BOARD with standard pelvic shielding versus standard pelvic shielding alone. *Cathet Cardiovasc Interv* 2015;85:Supp 2: S126. (abstr).

.89. Kahlon T, Kumar M, Kline C, Scott, E, Berger PB, **Blankenship JC**. Successful prevention of inappropriate cardiac catheterizations by an educational and screening program in a rural tertiary cardiac referral center. *Cathet Cardiovasc Interv* 2015;85:Supp 2: S122. (abstr).

.88. Doddamani S, Sun H, Forster K, Adams J, Henry Y, Fesniak H, **Blankenship J**, Berger P. Frequency and long-term outcomes of patients with asymptomatic left-ventricular dysfunction. *J Am Coll Cardiol* 2015;65:A191 (abstr).

.87. **Blankenship JC**, Vandermark WA, Pfeiffer J, Krex SM, Schneider TA, Berger. Improved case mix index due to imbedded clinical documentation improvement specialists on inpatient cardiology service at a tertiary medical center. *J Am Coll Cardiol* 2015;65:A243 (abstr).

.86. Mead N, Klein A, **Blankenship J**, Skelding K, Scott T, Berger P, Messenger J, Green S. The effects of the fellow involvement on fluoroscopy use, and contrast use during coronary angiography. *Cathet Cardiovasc Interv* 2013;81:S97.

- .85. Green S, Mead N, **Blankenship J**, Mulukutla S, Berger P. Impact of a novel curriculum comprising both didactic lectures and cardiac catheterization simulation on the skills, knowledge, and educational experience of cardiology fellows. *Cathet Cardiovasc Interv* 2013;81:S95.
- .84. Barn K, Akram MA, **Blankenship J**, Bower-Stout C, Carey D, Sun H, Skelding K, Scott, T, Berger P. Impact of pre-hospital ECG on time to treatment and clinical outcome in a rural regional STEMI network. *J Am Coll Cardiol* 2013;61:A28.
- .83. Yost GW, Puher SL, Scott TD, Skelding KA, Nardone D, Hodgson JMcB, Berger PB, **Blankenship JC**. The frequency and etiology of readmission in the 30 days after percutaneous coronary intervention. *J Am Coll Cardiol* 2011;58:B107.
- .82. Canady B., Collins C, **Blankenship J**, Mowery H. (2011, September). Partner influence on health behavior change in patients with heart disease. Poster presentation at the Annual Conference of the European Health Psychology Society, Hersonissos, Greece.
- .81. Canady B, Collins C, **Blankenship J**, Mowery H. (2011, September). Effects of relationship satisfaction and partner anxiety on behavior change in patients with heart disease. Poster presentation at the British Psychological Society Division of Health Psychology Annual Conference, Portsmouth, UK.
- .80. Acharya Y, Bhattarai J, Berger P, Skelding K, Scott T, Hodgson J, **Blankenship J**. High dose adenosine for no-reflow after percutaneous coronary intervention is safe and effective but may induce atrial fibrillation. *Cathet Cardiovasc Intervent* 2011;77:S115.
- .79. Yost G, **Blankenship JC**, Scott TD, Skeldign KA, Nardone D, Hodgson JM, Berger PB. Frequency and etiology of readmission in the 30 days after a percutaneous coronary intervention. *Cathet Cardiovasc Intervent* 2011;77:S81.
- .78. Haftbaradaran H, Scott T, Skelding K, Nardone D, Hodgson J, Berger P, **Blankenship J**. Etiology of in-hospital death after PCI in the current era. *Cathet Cardiovasc Intervent* 2011;77:S10
- .77. Crudu V, Blankenship JC, Skelding KA. Predictors of complications related to access site after PCI. *J Am Coll Cardiol* 2010;56:B118.
- .76. **Blankenship JC**, Berger PB, Scott TD, Skelding KA. Operator sleep deprivation from late night STEMI PCI does not increase next-day PCI complication rates. *J Am Coll Cardiol* 2010;56:B43.
- .75: Skelding KA, Berger PB, **Blankenship JC**, Mascarenhas VH, Good CW, Scott TD, Hodgson JM. Frequency of coronary angiography and revascularization among men and women with myocardial infarction and their relationship to mortality at one year: an analysis of the Geisinger Myocardial Infarction Cohort. *J Am Coll Cardiol* 2010;56:120A.
- .74. **Blankenship JC**, Zimmerman D, Scott T, Skelding KA, Buckley JW, Berger PB. PCI relief of angina is similar for typical versus atypical symptoms. *Cath Cardiovasc Intervent* 2009;73:S56.
- .73. **Blankenship J**, Shaw RE, Babb JD. Safety and efficacy of three strategies of multi-vessel percutaneous coronary intervention: Same session vs. multi-vessel vs. multi-hospitalization. *J Am Coll Cardiol* 2009;53:A29 (Abstr).
- .72. **Blankenship J**, Sartorius JA, Zimmerman DK, Skelding KA, Scott TA, Belles LM, Temple A, Berger PB. Enrollment in STEMI PCI trials is possible without increase in door to balloon times. *J Am Coll Cardiol* 2009;53:A51 (Abstr).
- .71. Welsh RC, Granger CB, Westerhout CM, **Blankenship J**, Holmes, DR, O'Neill WO, Hamon CW, Van de Werft FJ, Armstrong PW. Prior coronary artery bypass graft portends high risk in STEMI patients treated with primary percutaneous coronary intervention. *J Am Coll Cardiol* 2009;53:A322 (Abstr).
- .70. Skelding KA, Mascarenhas V, Berger P, Good C, Scott T, Buckley J, Wood C, Sartorius J, **Blankenship J**. A non-invasive strategy for the treatment of myocardial infarction is associated with 1-year mortality after correction for differences in baseline characteristics. *J Am Coll Cardiol* 2009;53:A55 (Abstr).

- .69. Skelding KA, Berger P, Mascarenhas V, Good C, Scott T, Buckley J, Sartorius J, Wood C, **Blankenship J**. Gender is an independent risk factor for mortality when a non-invasive strategy is employed in the setting of acute myocardial infarction. *J Am Coll Cardiol* 2009;53:A55 (Abstr).
- .68. Assal C, Martin B, Armstrong A, Diehl M, Torretti D, Shirani J, **Blankenship JC**. Relation of obstructive coronary atherosclerosis to disease activity in rheumatoid arthritis. *J Investigative Med* 2008; 56 (5): 810 (Abstr).
- .67. **Blankenship JC**, Scott, TD, Skelding KA, Berger PB, Parise H, Brodie BR, Witzemberger B, Gaugliumi G, Peruga J, Lansky AJ, Mehran A, Stone GW. Presentation to non-PCI hospital is major modifiable factor associated with delayed door-to-balloon time in HORIZONS-AMI. *Circulation* 2008;118:S903 (Abstr).
- .66. Kalyanasundaram A, Sartorius J, Scott T, **Blankenship JC**. A pooled analysis of 3 trials of bivalirudin versus heparin and glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention. *Am J Cardiol* 2008;102:79i (abstr.)
- .65. **Blankenship JC**, Sledgen M, Skelding KA, Scott T, Berger P, Sartorius JA, Donegan M, Menapace FJ. Efficient referring hospitals can routinely transfer patients for STEMI PCI with door-to-balloon times < 90 minutes. *J Am Coll Cardiol* 2008;51:A267 (Abstr).
- .64. Zimmerman DK, **Blankenship JC**, Skelding KA. Symptoms after stenting are unrelated to symptoms before or during stenting. *Circulation* 2007;116:II-677 (Abstr).
- .63. **Blankenship JC**, Sledgen M, Berger PB, Wood, GC, Skelding KA, Scott T, Menapace FJ, Donegan MA. Can STEMI patients transferred for primary angioplasty receive treatment within 90 minutes in a rural setting? *Circulation* 2007 *Circulation* 2007;116:II-431 (Abstr).
- .62. Good CW, Skelding KA, Patterson J, **Blankenship JC**, Scott T, Carey BC, Wywadis R. Analysis of patients at high risk of developing contrast-induced nephropathy. *Cathet Cardiovasc Intervent* 2007;69:S84 (Abstr).
- .61. Zimmerman DK, **Blankenship JC**. Pain during PCI predicts relief of symptoms after PCI. *Cathet Cardiovasc Intervent* 2007;69:S74 (Abstr).
- .60. Scott T, Good CW, **Blankenship JC**, Yoder SC. Ad hoc percutaneous coronary interventions: feasibility and obstacles in an efficient cardiac catheterization laboratory. *Cathet Cardiovasc Intervent* 2007;69:S73 (Abstr).
- .59. Carey BC, **Blankenship JS**, Skelding, KA, Sledgen M, Singh K. Rural patients transferred for STEMI PCI can meet the 90-minute door-to-balloon time guideline goal. *Cathet Cardiovasc Intervent* 2007;69:S70 (Abstr).
- .58. Hubbard CR, **Blankenship JC**, Zhang H, Kip KE, Williams DO. Procedural and angiographic adverse events during coronary interventions with paclitaxel and sirolimus stents: a DEScover Registry substudy. *Cathet Cardiovasc Intervent* 2007;69:S41 (Abstr).
- .57. Kalyanasundaram A, **Blankenship JC**, Famiglio L, McConnell T. Attitudes and perceptions of cardiology fellows towards virtual reality: results from a survey questionnaire on cardiac catheterization simulation training. *Cathet Cardiovasc Intervent* 2006;67: 796 (Abstr).
- .56. Aslam F, **Blankenship JC**. Percutaneous closure of patent foramen ovale: technical success and clinical outcomes of an infrequently-performed procedure. *Cathet Cardiovasc Intervent* 2006;67: 780 (Abstr).
- .55. **Blankenship JC**, Scott T, Singh K. Improvement in door-to-balloon times with a rapid transfer/treatment protocol independent of interventionists speed. *Cathet Cardiovasc Intervent* 2006;67: 746 (Abstr).
- .54. Haldis T, **Blankenship JC**. The feasibility of transport for primary PCI in the treatment of STEMI in a rural American setting. *J Am Coll Cardiol* 2005;45:193A (Abstr).

- .53. Gavlick K, **Blankenship JC**, Kleiman NS, Bittl JA, Feit F, Topol EJ, Lincoff AM. Procedural predictors of creatine kinase-MB elevations in the REPLACE-2 study. *J Am Coll Cardiol* 2004;43:44A (Abstr).
- .52. Mirza A, Al-Sadek M, Iliadis L, Chapman JC, Singh K, **Blankenship JC**. Does stent expansion to a diameter greater than the adjacent coronary artery contribute to peri-procedural cardiac enzyme elevation? *South Med J* 2003;10; supplement 45 (Abstr).
- .51. Elmi F, Wood GC, **Blankenship JC**. N-Acetylcysteine and contrast induces nephropathy in diabetic patients undergoing coronary angiography or intervention. *Cathet Cardiovasc Intervent* 2003;59:118. (Abstr)
- .50. Iliadis EA, Hamirani KI, **Blankenship JC**, Aji J. Patent foramen ovale closure in the cardiac catheterization lab; Impact of hypercoagulable state on clinical outcomes for patients undergoing percutaneous closure. *Cathet Cardiovasc Intervent* 2003;59:119. (Abstr)
- .49. Hamirani KJ, Iliadis EA, **Blankenship JC**, Aji J. Patent foramen ovale closure in the cardiac catheterization lab: 6 month clinical outcomes and comparison of sizing modalities. *Cathet Cardiovasc Intervent* 2003;59:119: B-41. (Abstr)
- .48. Kaddissi GI, Topalion SK, Elmi F, Aji J, **Blankenship JC**, Iliadis EA. Does residual stenosis after beta intravascular brachytherapy predict outcome? *Cathet Cardiovasc Intervent* 2003;59:125. (Abstr)
- .47. Puri R, Eisenberg MJ, **Blankenship JC**, Cugno S, Huynh T. Better functional status among U. S. than non-U. S. patients after percutaneous coronary intervention: an effect of medical care? *J Am Coll Cardiol* 2003;41: 521A. (abstr)
- .46. Exaire JE, Dauerman HL, Moliterno DJ, **Blankenship JC**, Hsu A, Raymond RE, Powers ER, Cohen EA, Topol EJ. Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices: results from TARGET. *J Am Coll Cardiol* 2003;41: 18A. (abstr)
- .45. Eisenberg MJ, Cugno S, Puri R, **Blankenship JC**, Huynh T, Starling M, Pilote L. Routine functional testing following percutaneous coronary intervention leads to increased clinical events in high-risk patients: results from the ADORE trial. *American Heart Assoc Annual Scientific Meeting, November 2002. Circulation* 2002;106:II-437. (abstr)
- .44. Mirza MA, Singh K, Scott T, Fenster BF, Blankenship JC, Chapman JH, Iliadis EA. Relationship between recurrent chest pain, coronary intervention and lesions with fractional flow reserve greater than .75. *Cath Cardiovasc Intervent* 2002;56:128. (abstr)
- .43. Mirza MA, Islam MA, Tadros GM, Singh K, Chapman JH, Blankenship JC, Iliadis EA. Is stent placement better than angioplasty alone for failed thrombolysis in acute myocardial infarction? *Cath Cardiovasc Intervent* 2002;56:117 (abstr)
- .42. Islam MA, **Blankenship JC**, McConnell T, Iliadis EA, Lincoff AM, Tcheng JE, Califf RM, Topol EJ. Effect of eptifibatid and abciximab in preventing creatinine kinase-MB elevation during percutaneous coronary intervention. *Cath Cardiovasc Intervent* 2002;56:122. (abstr)
- .41. Islam MA, **Blankenship JC**, McConnell T, Iliadis EA, Lincoff AM, Tcheng JE, Califf RM, Topol EJ. Do eptifibatid and bciximab prevent angiographic complications during percutaneous coronary intervention? *Cath Cardiovasc Intervent* 2002;56:123. (abstr)
- .40. Elmi F, Mukhtar H, **Blankenship JC**, McConnell T, Iliadis EA. Blood sugar level during percutaneous coronary intervention in diabetics: does it predict outcome? *Cath Cardiovasc Intervent* 2002;56:135. (abstr)
- .39. Singh K, Wood GC, **Blankenship JC**, Chapman JC, Iliadis EA. Angiographic characteristics affecting fractional flow reserve. *Cath Cardiovasc Intervent* 2002;56:127. (abstr)
- .38. Cugno S, Eisenberg MJ, **Blankenship JC**, Huynh T, Azrin M, Sedlis S, Pilote L. Impact of percutaneous Coronary Intervention on functional status: results from the ADORE Trial. *American College of Cardiology Annual meeting, March 2002. J Am Coll Cardiol* 2002;39:179A.
- .37. Bachour FA, **Blankenship JC**, Iliadis EA, Tasissa G, O'Shea CJ, Tcheng JE. Effect of glycoprotein IIb/IIIa receptor

- inhibition on in-lab adverse events and subsequent CK-MB elevation during percutaneous coronary intervention in ESPRIT. American College of Cardiology Annual meeting, March 2001. *J Am Coll Cardiol* 2001;37:84A. (abstr)
- .36. Singh G, Agarwal MD, Blankenship JC, McConnell TR. Hyperlipidemia management in patients undergoing percutaneous coronary intervention – a comparison of inpatient vs outpatient populations. *Cathet Cardiovasc Intervent* 2001;53:115
- .35. Islam MA, **Blankenship JC**, Tcheng JE. Effect of abciximab on in-laboratory adverse events during percutaneous coronary intervention with stents in the EPISTENT Trial. *Cathet Cardiovasc Intervent* 2001;53:98c (abstr)
- .34. Islam MA, **Blankenship JC**, Wood GC, Campbell BP, Iliadis EA. Can in-laboratory adverse events predict creatine kinase elevation during percutaneous coronary intervention? *Cathet Cardiovasc Intervent* 2001;53:101. (abstr)
- .33. Fenster BD, Scott T, Bachour FA, Menapace FJ, Chapman J, **Blankenship JC**, Iliadis EA. Correlation of a non-critical fractional flow reserve with functional test performance and long term clinical outcome. *Cathet Cardiovasc Intervent* 2001;53:103. (abstr)
- .32. Fenster BD, Padiyar K, McConnell TR, Menapace FJ, Chapman J, **Blankenship JC**, Iliadis EA. Intracoronary stent placement promotes more aggressive and complex coronary interventions with preserved procedural success rate. *Cathet Cardiovasc Intervent* 2001;53:119. (abstr)
- .31. Tolleson TR, Bittle J, O'Shea JC, Saucedo J, Levine G, Lopez M, Kitt MM, Lorenz TJ, **Blankenship JC**, Pacchiana CM, Natarajan M, Tcheng JE. Relationship between Maximum Procedural ACT and Safety/Efficacy in ESPRIT/IMPACT II. American Heart Assoc Annual Scientific Meeting, November 2000. *Circulation* 2000;102:II-665. (abstr)
- .30. Gilchrist IC, Pacchiana CM, Cantor WJ, **Blankenship JC**, Seidelin P, Ducas J, Sheldon W, Tannenbaum MA, Smith JE, O'Shea JC, Lorenz TJ, Tcheng JE. Temporal spectrum of ischemic complications with percutaneous coronary intervention: the ESPRIT experience. American Heart Assoc Annual Scientific Meeting, November 2000. *Circulation* 2000;102:II-640. (abstr)
- .29. Dasgupta H, Costello J, McConnell TR, **Blankenship JC**. Significance of ST elevation with dobutamine stress. American College of Cardiology Annual meeting, March 2000. *J Am Coll Cardiol* 2000;35:422A. (abstr)
- .28. Memon MA, Knight JA, Costello J, **Blankenship JC**, Menapace FJ. Does addition of echocardiography to exercise treadmill testing help in triage of low-risk chest pain patients in the emergency department? American Heart Assoc Annual Scientific Meeting, November 1999. *Circulation* 1999;100:I-452. (abstr)
- .27. **Blankenship JC**, Menapace FM, Demko SL. Incidence of thrombocytopenia complicating treatment with glycoprotein IIb/IIIa receptor inhibitors. American College of Cardiology Annual meeting, March 1999. *J Am Coll Cardiol* 1999;33:255A.. (abstr)
- .26. **Blankenship JC**, Godfrey N, Demko SL, Califf RM, Lincoff AM, Tcheng JE, Topol EJ. Elimination of excess vascular access site bleeding during coronary intervention with abciximab. American College of Cardiology Annual meeting, March 1999. *J Am Coll Cardiol* 1999;33:73A.. (abstr)
- .25. **Blankenship JC**, Menapace FM, Demko SL. Incidence of intra-cranial hemorrhage in trials of glycoprotein IIb/IIIa receptor inhibitor drugs. American College of Cardiology Annual meeting, March 1999. *J Am Coll Cardiol* 1999;33:41A.. (abstr)
- .24. **Blankenship JC**, Godfrey NK, Balog C, Demko SL, Califf RM, Lincoff AM, Tcheng JE, Topol EJ. CKMB enzyme rise after in-lab adverse events during coronary intervention in EPISTENT. American College of Cardiology Annual meeting, March 1999. *J Am Coll Cardiol* 1999;33:26A.. (abstr)
- .23. **Blankenship JC**, Godfrey NK, Balog C, Demko SL, Tcheng JE for the EPISTENT Investigators. How did abciximab decrease ischemic complications during coronary intervention in EPISTENT? Analysis of in-lab adverse events. American Heart Assoc Annual Scientific Meeting, November 1998. *Circulation* 1998;98:I-573. (abstr)
- .22. **Blankenship JC**, Anderson KM, Demko SL, Lincoff AM, Tcheng JE, Cabot CF. In-lab angiographic complications during coronary intervention with abciximab vs placebo in the EPILOG trial. American Heart Assoc Annual Scientific

Meeting, November 1997. *Circulation* 1997;96:I-162. (abstr)

.21. **Blankenship JC**, Anderson KM, Demko SL, Cabot CF, Kereiakes DJ, Aguirre FV. Decreased vascular access site bleeding after coronary intervention with abciximab in the EPILOG versus the EPIC trial. American Heart Assoc Annual Scientific Meeting, November 1997. *Circulation* 1997;96:I-161. (abstr)

.20. Talley JD, **Blankenship JC**, Werns S, Spokojny A, Landeau C, Anderson HV, White H, Bach R, Siegal R, Krucoff M, Raymond R, Little T, Waites T, Sharma S, Warren S, Bissett J, Green C, Rawert M, Pinkeston J, Hope M for the CRAC investigators. The relationship between coronary artery dissection and long-term clinical outcome: results from the CRAC (Compliance Related Acute Complication Trial). American College of Cardiology Annual Scientific Meeting, March 1997. *J Am Coll Cardiol* 1997; Suppl, 277A. (abstr).

.19. **Blankenship JC**, Hellkamp AS, Demko SL, Aguirre FV, Topol EJ, Califf RM for the EPIC Investigators. Vascular access site complications after percutaneous coronary intervention with glycoprotein IIb/IIIa receptor inhibitor therapy in the EPIC trial. American College of Cardiology Annual Scientific Meeting, March 1997. *J Am Coll Cardiol* 1997; Suppl, 277A. (abstr)

.18. Werns J, **Blankenship J**, Spokojny A, Landau C, Anderson HV, White H, Bach R, Siegal, Krucoff M, Raymond R, Warren S, Little T, Waites T, Sharma S, Shugoll W, Ledley G, Cooke D, Gershony G, Bissett J, Rawert M, Etko W, Hope M, Vogel R, Talley JD. The relationship between angiographic dissection and clinical complications: results of a prospective randomized clinical trial (CRAC). *Cathet Cardiovasc Diagn* 1996;38:118. (abstr)

.17. Aguirre FJ, Topol EJ, Ferguson JJ, **Blankenship JC**, Gardner LH, Caracciolo EA, Donohue TJ, Harrington RA, Tchong JE for the IMPACT II Investigators. Effect of glycoprotein (GP) IIb/IIIa antagonism with integrilin on activated clotting times during coronary interventions: results from the IMPACT II trial. American Heart Association Meetings, November 1996. *Circ* 1996 (suppl I);94:I-197. (abstr)

.16. **Blankenship JC**, Sigmon KN, Tardiff BE, Demko SL, Tchong JE for the IMPACT II Investigators. Effect of glycoprotein IIb/IIIa inhibition on specific in-lab complications of coronary intervention and resultant CK elevation on the IMPACT II trial. American Heart Association Meetings, November 1996. *Circ* 1996 (suppl I);94:I-198. (abstr)

.15. Ferguson JJ, McDonough TJ, Worley SJ, French WJ, Corbelli JC, **Blankenship JC**, Carey D, Aguirre FV, Harrington RA, Talley JD, Lincoff AM, Sheldon WC, Weiner BH, Resar JR, Tchong JE, Topol EJ, Califf RM for the IMPACT II Investigators. Clinical outcome of "high-risk" vs "elective" patients undergoing percutaneous coronary intervention: results from IMPACT II. *J Am Coll Cardiol* 1996; 27:180A.. (Abstr)

.14. Aguirre F, Ferguson JJ, **Blankenship JC**, Pieper KS, Taylor M, Harrington RA, Rund M, Caracciolo EA, Donahue TJ, Califf RM, Lincoff AM, Tchong JE, Topol EJ for the IMPACT II Investigators. Association of preintervention activated clotting times (ACT) and clinical outcomes following percutaneous coronary revascularization: results from the IMPACT II trial. *J Am Coll Cardiol* 1996; 27:83A.. (Abstr)

.13. Talley JD, **Blankenship J**, Werns S, Spokojny A, Landau C, Anderson HV, White H, Bach R, Siegal R, Krucoff M, Raymond R, Warren S, Bissett J, Rawert M, Etko W, Hope M, Vogel R. Compliance of balloon material does not effect angiographic dissection rate. Results from the CRAC (Compliant Related Acute Complication) study. *J Am Coll Cardiol* 1996; 27:54A.. (Abstr)

.12. **Blankenship J**, Mandak J, Aguirre F, Aguirre FV, Berkowitz SD, Gilchrist I, Sheikh K, Griffin J, McIvor M, Resar J, Weiner B, George J, Talley J, Timmis G, Lincoff M, Tchong J, Califf R, Topol J for the IMPACT II Investigators. Vascular access site complications during angioplasty with glycoprotein IIb/IIIa receptor inhibition in the IMPACT II trial. *J Am Coll Cardiol* 1996; 27:360A.. (Abstr)

.11. Bleich SD, Adgey AAJ, Pickering E, Hillis WS, Ghali M, **Blankenship J**, Madigan P, Bates E, Rees A, Love T for the DouBLE Trial Investigators. An angiographic assessment of the efficacy and safety of front-loaded and bolus regimens of activase. The double-bolus lytic efficacy trial. *Circ* 1995;92:I-415. (Abstr).

.10. Talley JD, Mauldin P, **Blankenship J**, Werns S, Spokojny A, Anderson HV, Landeau C, Bach R, White H, Raymond R, Siegal R, Warren S, Vogel R, Rawert M, Hope M and CRAC Investigators. Economic implications of the compliance of balloon material used in elective PTCA. *Circ* 1995;92:I-661. (Abstr)

- .9. Krucoff M, **Blankenship J**, Raymond R, Bach R, Friedman G, Finney J, Vogel R, Hope M, Rawert M, Talley JD for the CRAC Investigators. Inflation strategies used during elective PTCA: clinical outcome from the oscillating substudy of the CRAC trial. *Circ* 1995;92:I-725. (Abstr)
- .8. Talley JD, **Blankenship J**, Werns S, Spokojny A, Anderson HV, Landeau C, Bach R, White H, Raymond R, Siegal R, Warren S, Vogel R, Hope M, Rawert M, Etka W for the CRAC Investigators. Does the type of balloon material used in elective PTCA make a difference in clinical complications? Results from the CRAC study. *Circ* 1995;92:I-74. (Abstr)
- .7. Brener S, Cohen M, Talley JD, Eagle K, Gershony G, Chaitman B, Benitez RM, Ahmann D, **Blankenship J**, Domanski M, Ellis S. Striking hospital to hospital variation in preoperative cardiac workup for patients referred for major non-cardiac surgery. *Circ* 1995;92:I-679. (Abstr)
- .6. Ford A, Henry S, Fry C, **Blankenship J**. Slow oscillating vs. rapid inflation and slow vs. rapid deflation in PTCA. *J Am Coll Cardiol* 1994;35:1A.. (Abstr)
- .5. **Blankenship JC**, Telesford LA, Modesto TA. A randomized study of sheaths versus guidewires for arterial access during elective catheterization. *Circ* 1993; 8:I-251. (Abstr).
- .4. Wall TC, Topol EJ, Califf RM, **Blankenship JC**, Talley J, Tannenbaum M, Gacioch G, Cohen M, Sanz M, Leimberger J for the TAMI 9 Study Group. TAMI 9: Preliminary report of prospective randomized trial of IV fluosol in acute MI. *Circ* 1992; 86:I-642. (Abstr).
- .3. George SW, **Blankenship JC**, Torretti D. Serum sickness after streptokinase thrombolysis. *Arthritis and Rheumatism* 1992; 35(Supp):R5. (Abstr).
- .2. Grines CL, Nissen SE, Booth DC, Gurley JC, Chelliah N, **Blankenship JC**, Branco MC, Bennett K, DeMaria AN. A prospective randomized trial comparing combination half-dose tPA with streptokinase to full dose tPA in acute myocardial infarction. *J Am Coll Cardiol* 1990; 15:4A. (Abstr).
- .1. **Blankenship J**, Thomas W, Abrams G, Gallagher K, O'Neill W. Non-surgical percutaneous endarterectomy using a mechanical rotational catheter in normal canine coronary arteries in vivo. *J Am Coll Cardiol* 1987; 9(2):188A.. (Abstr)

## **Book Edited**

Practical Reporting of Cardiovascular Services and Procedures, American College of Cardiology. 1995, 1996, 1997, 1998, and 1999 editions, **JC Blankenship**, editor .

## **Book Chapters**

Schneider M, **Blankenship JC**. Thrombus aspiration, pros and cons. *Textbook of Catheter-Based Cardiovascular Interventions*. Springer. Copyright 2018. Pp869-879. DOI 978-3-319-55994-0\_52.

Brown E, **Blankenship JC**. Saphenous vein graft and arterial graft disease intervention, in American College of Cardiology Catheterization Self-Assessment Program v5 (ACC CathSAP 5). 2017.

Morrison D, **Blankenship JC**. Saphenous vein graft and arterial graft disease intervention, in American College of Cardiology Catheterization Self-Assessment Program v4. 2013. Chapter 9-3, p 9.3.1-9.3.12.

**Blankenship JC**, Berger PB. Pharmacology of intravenous glycoprotein IIb/IIIa antagonists. In *Antiplatelet Therapy in Ischemic Heart Disease*. Wiley-Blackwell, 2008. Chapter 7, pp 97-110.

**Blankenship JC**. Saphenous vein graft and arterial graft disease intervention, in American College of Cardiology Catheterization Self-Assessment Program v3. 2008. Chapter 62, p 732-751.

**Blankenship JC** and Sellers D. Emergency pacemaker use and evaluation. In Principles and Practice of Emergency Medicine, 4<sup>th</sup> edition, Schwartz GR editor. Williams and Wilkins, 1999, pp. 436-451.

**Blankenship JC** and Sellers D. Use and evaluation of pacemakers. In Principles and Practice of Emergency Medicine, Schwartz GR, Cayten CG, Mangelsen MA, and Mayer TA, eds. Lea and Febiger, 1992, pp. 641-665.

**Blankenship JC.** Pacemaker use: Indications and methods. In Emergency Medicine: The Essential Update, 1989. Schwartz GR, Bircher N, et al, eds. W.B. Saunders Co., pp. 227-271.

**Blankenship JC,** and Thomas RB. Improved health services and increasing population pressure in an Andean community. In Health in the Andes, 1981, pp. 151-172.

## **Presentations at Scientific Meetings** (different from abstracts listed above)

Singh K, Iliadis EA, Islam A, **Blankenship JC.** Assessment of physiological significance of intermediate grade ostial left main stenosis. Cardiology Fellows Forum of Excellence 2001, American Heart Association Annual Scientific Sessions, Nov 10 2001, Anaheim CA.

Scheiber JE, **Blankenship JC,** Menapace FJ. Feasibility of communicating catheterization results to referring physicians by telephone. Pennsylvania Chapter of the American College of Cardiology Annual Scientific Meeting, Pittsburgh, PA, October 1996.

**Blankenship JC,** Nguyen D, Ford A. Oscillating balloon angioplasty: Does the balloon see the pressure oscillation? American College of Cardiology, Pennsylvania Chapter of the American College of Cardiology Annual Scientific Meeting, Pittsburgh, September 1994.

Ford A and **Blankenship JC.** Ultra-slow vs rapid balloon inflation and deflation in coronary angioplasty. American College of Cardiology, Pennsylvania Chapter of the American College of Cardiology Annual Scientific Meeting, Pittsburgh, September 1992.

Bergen P, **Blankenship J,** Das S, Buda A. Doppler echocardiographic evaluation of load reduction therapy in dilated cardiomyopathy. Am Fed Clin Res 1989, Washington, DC, national meeting.

## **Lectures and Addresses: 2009**

Mercy Hospital (Scranton) catheterization conference: February 5: ASD/PFO closure  
Logan Hope School 4<sup>th</sup>/5<sup>th</sup> grade: February 9: Cardiovascular physiology and health  
Danville Community Center Healthy Living Series: February 11: Heart Attack  
Geisinger Medical Center Aortic Disease Symposium: Feb 28: Is a Level 1 Aortic Disease Program Feasible?  
Susquehanna Health System Hospital Cardiology Department: March 2: ASD/PFO closure  
GMC Interventional Cardiology Conference: March 12: 2008 3<sup>rd</sup> Quarter NCDR Results and Acute MI Lytic/PCI Rx  
GHS Women's Cardiovascular Health Group: March 24: ASD/PFO Closure  
American College of Cardiology Annual Scientific Session: Safety and Efficacy of Staged PCI: oral abstract  
American College of Cardiology Annual Scientific Session: Multi-vessel PCI: Talk at session  
Acute Coronary Syndromes: May 5: Internal Medicine noon conference  
Cardiology Coding and Reimbursement: May 6: Chaired session at the SCAI Annual Scientific Session  
Cardiology Procedure Valuation, SCAI Annual Scientific Sessions: May 6  
Cardiology Dept Didactic Conference: Informed Consent: July 2, 2009  
How to Write About Scientific Research: Cardiology Dept Didactic Conference: 9/17/09  
Interventional cardiology Research: Cardiology Dept Didactic Conference (1/2 hr): 9/25/09  
Level 1 and Level 2 Heart Attack Programs: Berwick Hospital: 10/6/09-PCI vs CABG for LMCA and CTO lesions:  
Cardiology Dept Didactic Conference: 10/15/09  
PCI vs CABG vs Medical Therapy for other lesion subsets: 10/29/09  
SLAMI GAPP Project: Efforts to Reduce Acute MI Mortality: GWV Heart Hospital: 11/12/09

## **Lectures and Addresses: 2010**

Level 1 and Level 2 Heart Attack Programs: GMC Emergency Department Residents' Conference: 1/26/10  
Level 1 and Level 2 Heart Attack Programs: St Catherine's Reg Med Cntr, Ashland PA: 2/1/10  
Level 1 and Level 2 Heart Attack Programs: Sunbury Community Hospital, Sunbury, PA: 3/24/10  
Level 1 and Level 2 Heart Attack Programs: Shamokin Hospital, Shamokin, PA: 3/25/10  
Level 1 and Level 2 and Evangelical Heart Attack Programs: Evangelical Hospital, Lewisburg, PA: 4/7/10  
GAPP SLAMI Project: ICU Staff, Geisinger Medical Center: 4/19/10  
Acute STEMI Case Presentation: "Knights of the Round Table" Conference, TCT: September 22, 2010  
The Relative Value Update Committee Process: Transcatheter & Cardiovascular Therapeutics: September 25, 2010

Update on STEMI: Geisinger Annual CME Symposium: September 29, 2010  
Update on STEMI: Primary Care of the Geriatric Patient CME Conference: November 10, 2010  
CPT and RUC Update 2011: American Medical Association Annual CPT Symposium: November 12, 2010  
New Cath Codes for 2011: Geisinger Coding and Reimbursement Dept: November 15, 2011

### **Lectures and Addresses: 2011**

Use and Calculation of SYNTAX scores in clinical practice: Cardiology Dept Cath Conf: 1/6/11  
Level 1 Heart Attack program: Washington Hospital Center cath lab webinar: 1/19/11  
Staging of PCI in Multi-vessel Cor Disease Pt I: Cardiology Dept Cath Conf: 2/8/11  
Interesting Cases Studies in PCI for MVCAD: Cardiology Dept Conf: 2/2/11  
Staging of PCI in Multi-vessel Cor Disease Pt II: Cardiology Dept Cath Conf: 3/3/11  
Causes of False-Negative FFR: Cardiology Dept Cath Conf: 3/10/11  
Integrated Referral System for STEMI PCI: Mission Lifeline statewide webinar: 3/10/11  
Geisinger Health System ProvenPCI Program: ACC Annual Scientific Session, 4/3/11  
Update on 2011 Valuation of Cardiac Procedures: ACC Annual Scientific Session, 4/4/11  
Level 1 Heart Attack program: Lewistown Hospital: May 31, 2011  
Cath Lab Quality and PCI Readmissions: WA state COAP Quality Conference, 6/1/11  
The AMA Relative Value Survey Process: Am Coll Cardiology national webinar, 6/13/11  
Informed Consent: Cardiology Dept Cath Conf: 7/8/11  
Treatment of Stable Coronary Disease: The 2011 PCI guidelines: Am Heart Assoc Sci Sess, Orlando FL, 11/16/11  
National Webinar: the 2011 PCI Guidelines, Soc for Cardiac Angiography/Interventions, 11/17/11  
Cardiology Reimbursement Changes for 2012: American Med Assoc Annual CPT/RUC Symposium, Chicago, 11/17/11  
National Webinar: Cardiology Reimbursement Changes for 2012: American Coll Cardiol, Nov 30, 2011  
Maryland Dept of Health Commissioners: 2011 AHA/ACC PCI Guidelines for Non-Surgery Hospitals, 12/14/11  
State-wise webinar for AHA Mission Lifeline: 2011 AHA/ACC PCI Guidelines for STEMI. 12/15/11

### **Lectures and Addresses: 2012**

Update on Cardiology Reimbursement: March 2012: American Coll of Cardiology Annual Scientific Session, Chicago  
Cardiology Procedural Reimbursement: March 2012: SCAI Emerging Leadership Forum, Chicago  
Health Care Reform and New Payment Models: May 17 2012, Baystate Med Ctr Plotkin CV Symposium, Springfield MA  
Negotiation and Conflict Resolution: Geisinger Cardiology Dept conference, Danville PA, November 12, 2012

### **Lectures and Addresses: 2013**

2013 Coding Update: Sweeping Changes in Cardiology Coding in 2013: SCAI/ACC/HRS webinar, Nov 28, 2012  
Translating Coding into Cardiology Reimbursement. ACC Ann Scientific Sessions. Mar 13, 2013, San Francisco, CA  
Health Care Payment Reform. SCAI Annual Scientific Sessions, May 9 2013. Orlando FL  
New Health Care Models. SCAI Think Tank Conference, SCAI Annual Scientific Sessions, May 8 2013, Orlando FL  
From Cardiology Coding to Cardiology Payment. Harvard School of Public Health, May 7 2013  
Health Care Payment Reform. Geisinger Resident Conference, May 15, 2013  
Negotiating for Physicians. Geisinger Medical Center Grand Rounds. Danville PA. August 2, 2013  
Northeastern Pennsylvania Level I Heart Attack Program Update, Danville PA. October 28, 2014.

### **Lectures and Addresses: 2014**

Cardiology Coding/Reimbursement. Emerging Leadership Mentoring program at ACC Annual Sci Sessions, Mar 2014  
Procedural Privileging. SCAI Annual Scientific Sessions. Las Vegas. May 28 2014  
Procedural Privileging. Geisinger fellows' didactic conference. June 6 2014  
Evolving Trends in STEMI PCI. NE Regional Meeting of Soc of CV Professionals. Philadelphia. June 12 2014.  
Evolving Trends in STEMI PCI. Geisinger fellows' didactic conference. June 20 2014  
Commencement Address for Geisinger Cardiovascular Technology School, June 26 2014  
Building a Winning Research Team. Transcatheter Cardiovascular Therapeutics, Washington DC, Sept 14, 2014  
Stable Ischemic Heart Disease Guidelines. Great Wall Internat'l Congress of Cardiology, Beijing, China, Oct 17, 2014

### **Lectures and Addresses: 2015**

Global Cardiovascular Health. 4TS Conference, Dubai, United Arab Emirates (UAE), Feb 19 2015  
Stable Ischemic Heart Disease Guidelines for Catheterization and PCI. 4TS Conf, Dubai, UAE, Feb 19 2015  
Accountable Care Act & Interventional Cardiol Reimbursement. Card Revasc Therapies, Washington DC, Feb 23, 2015  
Presidential Address: Optimism and Interventional Cardiology. SCAI Annual Scientific Sessions, San Diego, May 8 2015  
Hospital Credentialing and Privileging. SCAI Annual Scientific Sessions, San Diego, May 8 2015.  
SCAI: History and Opportunities. SCAI Annual Scientific Sessions, San Diego, May 8 2015.

New Developments in Interventional Cardiology. Mended Hearts Annual Meeting, Orlando, June 27 2015  
 Role of the Heart Team in Interventional Cardiology. Transcatheter Therapeutics (TCT), San Francisco, Oct 23, 2015  
 Guide Catheters and Guidewires, Asian Interventional CV Therapeutics, Dhaka Bangladesh, Nov 12, 2015  
 How To Do STEMI PCI. Asian Interventional CV Therapeutics, Dhaka Bangladesh, Nov 12, 2015  
 Cath Lab Complications and management. Asian Interventional CV Therapeutics, Dhaka Bangladesh, Nov 12, 2015  
 Does Transradial Access Decrease Mortality? Asian Interventional CV Therapeutics, Dhaka Bangladesh, Nov 13, 2015  
 Thrombus Aspiration in STEMI PCI, Asian Interventional CV Therapeutics, Dhaka Bangladesh, Nov 14, 2015  
 Dual Anti-Platelet Therapy. Asian Interventional CV Therapeutics, Dhaka Bangladesh, Nov 14, 2015  
 Ad Hoc PCI and Staged MV PCI. SCAI Fall Fellows Course, Dec 8, 2015.  
 Does Transradial Access Decrease Mortality? ACC "Cardiology Today and Tomorrow", Muscat, Oman, Dec 18 2015  
 Thrombus Aspiration in PCI, ACC "Cardiology Today and Tomorrow", Muscat, Oman, Dec 18 2015  
 Dual Anti-Platelet Therapy. ACC "Cardiology Today and Tomorrow", Muscat, Oman, Dec 19 2015

### **Lectures and Addresses: 2016**

How to Deal with Appropriate Use Criteria for PCI. Chronic Revascularization Therapy (CRT), Wash DC, Feb 24 2016  
 Race, Socioeconomic Factors, and Survival after MI. Assoc of Black Cardiologists Symposium, Wash DC, Feb 24, 2016  
 STEMI Fatigue: How to Prevent Erosion of D2B When STEMI PCI is Routine, CRT Mtg, Wash DC, Feb 23, 2016  
 Health Care Reform. Cardiovascular Service Line webinar, Geisinger, Danville, PA March 29, 2016  
 Conflict Resolution and Negotiation. Am Coll Cardiol Annual Sci Sessions, Chicago, April 3 2016  
 Cath Lab Quality. Am Coll Cardiol Annual Sci Sessions, Chicago, April 3 2016  
 Sub-Specialty Designation for Interventional Cardiology. Am Coll Cardiol Annual Sci Sessions, Chicago, April 3 2016  
 Coding, Payment, and How Cardiologists Can Survive Health Care Reform: SCAI Early Leader mentoring; 4/3/16  
 Radiation Safety: Saudi Arabian Cardiac Interventional Society annual meeting (SACIS 2016), Dammam, KSA, 4/15/16  
 Guidewires and Guide Catheters: SACIS 2016, Dammam, Kingdom of Saudi Arabia, 4/15/16  
 Is Radial Access the Preferred Route in 2016?: SACIS 2016, Dammam, Kingdom of Saudi Arabia, 4/16/16  
 Cath Lab Budgeting for 2016: SCAI Annual Scientific Sessions, Orlando, FL. May 5 2016  
 Presidential Address: SCAI Annual Scientific Sessions, Orlando, FL. May 5 2016  
 Presidential Oration: Intervent'l Cardiol in the Present Era. Cardiol Soc of Nepal Annual Mtg, Kathmandu, Nepal 11/3/16  
 Value of Separate Specialty Designation by CMS, SCAI national webinar, 11/16/16  
 The Future of Bioresorbable Vascular Scaffolds, VuMedi National Webinar, 11/30/16  
 Thrombus Aspiration in Acute MI: Cardiology Soc of India Annual Meeting; Kochi, India, 11/8/16  
 Decision-Making in Post CABG Patients: Cardiology Soc of India Annual Meeting; Kochi, India, 11/9/16  
 Presidential Conclave: Update on Bioresorbable Vascular Scaffolds; Cardiol Soc of India Ann Mtg; Kochi, India, 11/9/16  
 Tips and Tricks of Radial Access: Cardiology Soc of India Annual Meeting; Kochi, India, 11/9/16

### **Lectures and Addresses: 2017**

South African Society for Cardiovascular Intervention, Johannesburg, South Africa, January 27/28, 2017  
 ---Thrombus Aspiration in STEMI  
 --- Radial Access for PCI  
 --- PCI in Saphenous Vein Grafts  
 --- Case presentation: Thrombus Aspiration of SVG in STEMI  
 CRT Meeting, Washington, March 2017  
 ---STEMI Fatigue  
 ---Dealing with the Appropriate Use Criteria for PCI in 2017  
 Ochsner Heart Institute, March 23, 2017  
 ---Health Care Reform: How Cardiologists Can Thrive  
 Cardiology Society of India National Interventional Council, April 14-16, New Delhi, India  
 ---The Future of Interventional Cardiology  
 ---PCI in the Anti-Coagulated Patient  
 ---Multi-Vessel PCI  
 ---Update on Bioresorbable Vascular Scaffolds  
 ---Potential Mechanism of Stroke in Aspiration Thrombectomy for STEMI  
 Society for Cardiovascular Angiography and Interventions Annual Scientific Sessions, New Orleans, May 10-14  
 ---Credentialing and Privileging for the Cath Lab  
 ---American College of Cardiology: Past, Present, and Future  
 Geisinger Medical Center Fellowship Didactic Series  
 ---Informed Consent for Invasive Procedures  
 Cardiology Society of Nepal, Kathmandu Nepal, November 4, 2017  
 ---Update on Bioresorbable Vascular Scaffolds

- Left Main Coronary Artery Revascularization: The PCI Option
- Radial Artery Access Tips and Tricks

### **Lectures and Addresses: 2018**

CRT Meeting, Washington DC, March 2018

- Dealing with the Appropriate Use Criteria for PCI in 2018

Society for Cardiovascular Angiography and Interventions Annual Scientific Sessions, New Orleans, April 2018

- PCI for Angulated and Tortuous Lesions

University of New Mexico grand rounds, Oct 11 2018, Albuquerque, NM

- Cognitive Biases in Interventional Cardiology

Beth Israel Deaconess Hospital grand rounds (Shiu Ho Memorial Lecture) October 12, Boston, MA

- Cognitive Biases in Interventional Cardiology

Cardiology Society of Nepal, Kathmandu, Nepal, November 2-3, 2018

- Accessing the Arm: New Strategies

- Cognitive Biases in Interventional Cardiology

### **Lectures and Addresses: 2019**

CRT Meeting, Washington DC, March 2019

- How to Prevent Readmissions after MI

### **Additional Training**

American College of Cardiology Advanced Cardiology Leadership Workshop, 2/21-22, 2008, Washington DC

Media Spokesperson Training, Geisinger Medical Center, November 3, 2009

Executive Leadership Coaching, Geisinger Medical Center, June 2009 – March 2010

Hands-on Trans-Septal Catheterization Course, Lenox hill Hospital, New York City, February 2010

Harvard School of Public Health Masters in Health Care Management, 2012 – 2014

Effective and Legal Interviewing Techniques, Geisinger Health System, November 5, 2014.

Behavioral Interviewing, Geisinger Health System, November 17, 2014

Building High Performance Teams, Geisinger Health System, March 10, 2015

Emotional Intelligence as a Leadership Strategy, Geisinger Health System, July 27, 2017

Lean for Leaders, Geisinger Health System, July 27, 2017

**Funded Research: (Principal Investigator at Geisinger) (Funded by industry except as noted.)**

Year	Trial	Patients Recruited	Grants/Support
2016-17	IC-HOT: Super-saturated oxygen to minimize reperfusion injury after PCI for anterior STEMI	5	37,500
2016-17	Evolve Short DAPT	4	4000
2016-17	Artemis: informed consent	103	51,000
2015-17	St Jude Medical ASO registry	6	\$15,000
2015-16	Bionics stent	15	78,800
2013-14	REGULATE PCI	22	93,600
2013-14	STENTYS Apposition V self-expanding stent in acute MI	10	62,200
2013	PHOENIX Economics: Economic evaluation of PHOENIX Trail	68	9,000
2013-14	EVOLVE II: standard DES vs bio-absorbable polymer DES	17	89,400
2013-14	ADVISE II: iFR evaluation of angiographically intermediate lesions	5	\$16,500
2014	TRYTON bifurcation stent	1	20,100
2013-14	EXCEL: LMCA stenting vs CABG	6	26,700
2011-12	TOTAL: aspiration vs no aspiration before STEMI PCI	70	70,000
2011-12	VERDICT: FFR vs IVUS to assess angiographically intermediate lesions	49	254,000
2011-12	PHOENIX-CHAMPION: Cangrelor vs clopidogrel for PCI	71	213,000
2009-10	PROTECTION AMI: Inhibition of $\delta$ -PROTEin kinase C for the reduction of infarct size in Acute Myocardial Infarction	17	87,125
2008-09	REVEAL: Randomized, Multi-Center, Double-blind, Placebo Controlled Trial of the Effects of Erythropoietin on Infarct Size and Left Ventricular Remodeling in Survivors of Large Myocardial Infarctions	14	88,200
2008-10	SATURN: Study Of Coronary Atheroma By Intravascular ultrasound: Effect Of Rosuvastatin Versus Atorvastatin - A 104-Week, Randomized, Double-Blind, Parallel Group, Multi-Center Phase IIIb Study Comparing The Effects Of Treatment With Rosuvastatin 40mg Or Atorvastatin 80mg On Atherosclerotic Disease Burden As Measured By Intravascular Ultrasound In Patients With Coronary Artery Disease	2	30,400
2007-09	TRACER: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety And Efficacy Of SCH 530348 In Addition To Standard Of Care In Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist For Clinical Event Reduction In Acute Coronary Syndrome	29	337,560
2007-08	ERASE MI: A Randomized Trial To Evaluate The Effect Of Adjunctive Antiplatelet Therapy With Intravenous Prt060128, A Selective P2Y12-Receptor Inhibitor, Before Primary Percutaneous Intervention In Patients With St-Elevation Myocardial Infarction	21	98,700

2006-08	PLATO: A Study Of Platelet Inhibition And Patient Outcomes A Randomized, Double Blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes	2	12,200
2006-08	CHAMPION PLATFORM: A Clinical Trial Comparing Treatment With Cangrelor (In Combination With Usual Care) To Usual Care, In Subjects Who Require Percutaneous Coronary Intervention	58	255,200
2005-08	HORIZONS-AMI: 2 x 2 for Drug-eluting vs Bare Metal stents, and Bivalirudin vs Heparin/2b/3a Inhibitor	33	208,725
2004-6	SEPIA-PCI: Phase II study of Factor Xa inhib otamixaban versus heparin in PCI	8	56,000
2005-07	AMIHOT II-Therox AO System-A prospective multicenter randomized study of aqueous therapy for 90 minutes in anterior acute myocardial infarction patients with successful reperfusion (via PCI)	27	91,000
2005-07	SHINE- A Randomized Dose Ranging Study of Hexadecasaccharide including Active Control, in Patients with Unstable Angina or Non-ST-segment Elevation Myocardial Infarction Scheduled to Undergo Percutaneous Coronary Intervention.	1	4,500
2004-	DEScover Registry	60	12,000
2005-	STRADIVARIUS-Strategy To Reduce Atherosclerosis Development Involving Administration of Rimonabant-The IVUS study	8	96,000
2005-	COSTAR- Cobalt Chromium stent with antiproliferative for restenosis II Trial	25	148,750
2005-	MERLIN Metabolic efficiency with ranolazine for less ischemia in non-ST elevation ACS-TIMI 36	1	5,160
2004-05	APEX-AMI: Assessment of pexelizumab in acute MI	5	117,600
2003-05	SPIDER: Efficacy of the ev3 SPIDER distal protection filter for vein graft PCI	11	33,000
2003-04	PROTECT-TIMI 30:A randomized trial to evaluate the relative protection against post-pci microvascular dysfunction and post-PCI ischemia among anti-platelet and anti-thrombin agents	19	53,200
2003-04	S7 Registry: Registry of patients receiving the Medtronic AVE S7 stent	50	5,000
2003-07	CARDIA PFO closure system	3	3,600
2003	ASTEROID: Efficacy of rosuvastatin in preventing plaque progression as assessed by baseline and followup IVUS studies.	11	99,275
2002-03	PRIDE: Efficacy of the Kensey Nash Triactiv distal protection system for vein graft coronary interventions	5	7,500
2002-03	PPAR: Safety and effectiveness of rosiglitazone in post-PCI patients to prevent MACE events in the next year	9	22,500
2002	ETC 216: Efficacy and safety of IV infusions of ETC-216 in short-term reduction in plaque burden assessed by IVUS	1	9,509
2001-03	SYNERGY: Safety and effectiveness of lovenox in patients with ACS scheduled	3	6,000

	for cardiac cath and ad hoc intervention		
2001-02	REPLACE II: Bivalirudin to decrease ischemic and bleeding complications of coronary intervention	58	116,000
2001-03	NORMALIZE: Intra-vascular ultrasound assessment of non-critical coronary lesions with 2-year repeat IVUS (co-PI)	16	158,000
2001-02	MANTRA: randomized study of prayer and noetic therapies before coronary intervention	101	2,000
2000	Long-term followup of EPIC, EPILOG, and EPISTENT	--	18,000
2000	TARGET: tirofiban vs. abciximab with coronary stenting	23	41,267
2000	PRESTO: Tranilast to prevent restenosis after coronary stenting	6	19,275
1999-00	ESPRIT: eptifibatide vs. placebo in coronary stenting	21	45,250
1999-04	Open Artery Trial: PTCA vs. conservative therapy for occluded coronary arteries after MI. (Funded by the NIH)	4	4,000
1999	ASIS 1107: Phase 2 study of direct Factor 10 inhibitor in PTCA	3	3,750
1998-9	HALT-MI: Leukocyte receptor inhibitor in direct PTCA for acute MI	6	51,600
1998-00	ADORE: routine vs. clinically indicated exercise testing after PTCA	50	10,500
1997-8	OPUS: stent vs. PTCA for coronary intervention OPUS perfusion balloon substudy: PTCA with conventional vs. perfusion balloons	11	550
1997-8	EPISTENT: stent vs. stent+Reopro vs. PTCA+Reopro in elective PCI	47	139,350.
1996-7	RAPPORT: ReoPro vs. placebo in direct angioplasty for acute MI	19	19,200.
1996	Serum Sickness Rxns after Streptokinase. (Funded by Geisinger Research Found.)	18	10,800.
1996	TIMI 10B: TNK-tPA vs. tPA for acute MI	9	31,000.
1995-6	RAPID: monorail vs. over-the-wire balloons in angioplasty	19	4,750.
1995	EPILOG: c7E3 monoclonal antibody (abciximab) in moderate risk PTCA	70	199,500.
1993-5	CRAC: compliant vs. non-compliant balloons in PTCA	168	10,080.
1993-5	SLOFI (substudy of CRAC): oscillating vs. fast inflation in PTCA	168	0
1993-5	tPA double-bolus study: Double bolus vs. accelerated tPA in acute MI	23	85,000.
1993-5	Intra-coronary tPA study: dose-ranging trial of IC tPA for coronary thrombus	7	24,500.
1994	IMPACT II: integrelin vs. placebo in PTCA	101	252,500.
1993	Cholesterol embolization after tPA: incidence of cholesterol embolization after MI in patients with vs. without tPA (Funded by Geisinger Research Foundation)	63	9,200.
1992-3	EPIC: c7E3 monoclonal antibody (abciximab) in high-risk PTCA	66	217,800.

1992-3	TAMI-9: fluosol vs. placebo in MI	56	164,400.
1989	KAMIT (Kentucky Acute Myocardial Infarction Trial): tPA vs. tPA + SK for AMI	5	0
<b>Total</b>		963	\$4,460,276